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The presence of persistent man-made chemi-
cals in our environment is not a new problem.
However, it was not until the beginning of the
1960s that environmental pollutants aroused
debate and concern. Since then, a large num-
ber of chemicals have been identiﬁed in envi-
ronmental samples, and the time trends of
their concentrations have been the subject of
continuous interest. Apart from the heavy
metals, the group of chlorinated hydrocarbons
includes many pollutants regarded as major
environmental problems, e.g., the well-known
polychlorinated biphenyls (PCBs), polychlori-
nated dibenzodioxins (PCDDs) and dibenzo-
furans (PCDFs), the two latter groups
generally called dioxins. The PCBs and diox-
ins and their harmful effects on nature and
man have been extensively reviewed. Today
the effects of these substances are quite well
known, although their mechanism(s) of action
remains largely unsolved. The toxicity of these
chemicals and their presence in certain food
items, mostly of animal origin, have resulted
in introduction of dietary restrictions and rec-
ommendations by food administrations in dif-
ferent countries. Continuous monitoring of
the environmental levels of these chemicals
has shown a decreasing trend in their occur-
rence over the last 10 years or more in many
Western countries. 
There are significant amounts of other
chemicals in our environment that we know
less about, and one such group is the bromi-
nated flame retardants. Even today, limited
amounts of data are available on these com-
pounds, with regard to their presence and lev-
els in various products, environmental levels,
transformation products, disposition, and
toxic effects. Earlier overviews have compiled
the present knowledge about brominated
ﬂame retardants (1–7).
Polybrominated diphenyl ethers (PBDEs)
constitute an important group of brominated
ﬂame retardants. The compounds are mostly
found in ready-made plastic products.
PBDEs are used in large quantities worldwide
and are persistent in the environment, possi-
bly because the compounds are in the tech-
nosphere and will be released into the
environment for years to come. Over the last
10–15 years, there have been indications of
increased environmental and human levels of
these compounds, although the levels are still
lower than those for PCBs and DDT.
Therefore, it is important to summarize the
present state of knowledge about the environ-
mental occurrence, human exposure, and tox-
icity of PBDEs to assess health consequences
from the present and future use of this group
of brominated compounds. This article
reviews risks from PBDEs, with special
emphasis on dietary risks. 
Chemical and Physical
Properties of PBDEs
The general chemical formula of a PBDE is
C12H(9–0)Br(1–10)O, with the sum of H and
Br atoms always equal to 10. Structure for-
mulas are given in Figure 1.
The theoretical number of possible con-
geners is 209 and is divided into 10 congener
groups (mono- to decabromodiphenyl
ethers). However, compounds with less than
four bromine atoms are generally not found
in commercial PBDE products. The number
of PBDE congeners used in commercial
products, and thus found in environmental
samples, is quite small compared to the num-
ber of PCB congeners commonly found.
PBDE congeners are often numbered accord-
ing to the International Union of Pure and
Applied Chemistry (IUPAC) system origi-
nally designed for PCBs (8). Commercial
PBDEs are quite resistant to physical, chemi-
cal, and biologic degradation. The boiling
point of PBDEs is between 310 and 425°C
and their vapor pressure is low at room tem-
perature. PBDEs are lipophilic, and their sol-
ubility in water is low, especially for the
higher brominated compounds. The n-
octanol–water partition coefficient, log Pow,
ranges between 4.3 and 9.9. Physical proper-
ties are summarized in Table 1.
Analytical Methods
Extraction methods normally used for envi-
ronmental (biologic and sediment) samples
are batch or Soxhlet extraction. Different
methods of cleanup are used depending the
nature of other compounds analyzed and the
type of analytic method. Among these proce-
dures are sulfuric acid cleanup and different
types of column separations (e.g., silica gel,
aluminum oxide, and gel permeation chro-
matography). Recently supercritical fluid
extraction also has been described (9). Gas
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chromatography (GC) analysis is normally
done on capillary columns with methyl or
methyl plus 5% phenyl packing substrates.
Detection is made on an electron capture
detector (mass spectrometry–electron impact
ionization or mass spectrometry–electron cap-
ture negative ionization). The high-bromi-
nated diphenyl ethers with longer retention
times are analyzed using a shorter GC col-
umn. More details on PBDE analysis are
given in International Programme on
Chemical Safety (IPCS) (2) and by Sellström
(10,11). See also Örn (12), Haglund et al.
(13), and Sellström et al. (14) for further
details.
Pure PBDE congeners are needed to
unequivocally identify a PBDE congener.
Örn et al. (15,16) have described the synthe-
sis and characterization of tetra-, penta-, and
hexa-bromodiphenyl ethers. Recovery experi-
ments on tetraBDE (DE-47) and pentaBDEs
(DE-99 and DE-100) show that acceptable
recoveries are made in ﬁsh (111–114%) and
in sediment (106–140%) (14). 
In experimental studies, it is also beneﬁcial
to use synthesized PBDE congeners of high
purity to circumvent impurity problems. In
commercial PBDEs the presence of contami-
nants might otherwise affect the results of
studies. Consequently, it is important to know
the impurity profiles of the PBDE prepara-
tions being studied. Up to now, such data are
often missing. One type of contaminants that
could be found are the PBDDs and PBDFs.
These compounds could be formed during
heating of PBDE mixtures, but the toxic
2,3,7,8-substituted compounds seem to be
produced in minute amounts (17,18).
Production and Use of PBDEs
Commercial PBDEs are synthesized by
bromination of diphenyl ethers under condi-
tions resulting in mixtures of brominated
diphenyl ethers. The commercial products
predominantly consist of penta-, hepta-,
octa-, and decabromodiphenyl ethers.
Chemically, the pentabromo product is a
mixture primarily of tetra and penta con-
geners, and the octabromo product consists
mainly of hepta and octa congeners (Table
2). Consequently, almost no data are avail-
able on mono-, di-, tri-, hexa-, and nona-
diphenyl ethers. The number of different
congeners found in each commercial product
is relatively small. The composition of com-
mercial brominated diphenyl ethers is given
in Table 2.
PBDEs are used only for ﬂame retardant
purposes. The rationale for using brominated
compounds as flame retardants is based on
the ability of halogen atoms, generated from
the thermal decomposition of the bromo-
organic compound, to chemically reduce and
retard the development of ﬁre. Factors favor-
ing the use of PBDEs are therefore the high
bromine content (which means good flame-
retardant properties), thermal stability, and
relatively low cost. They are used as additive
ﬂame retardants at concentrations of 5–30%
in many different polymers, resins and sub-
strates, and common plastics, including acry-
lonitrile butadiene styrene and high impact
polystyrene (19). Additive flame retardants
leach and escape from the finished polymer
product more easily than reactive ﬂame retar-
dants. Examples of products containing ﬂame
retardants, and especially PBDEs, include
many components of electronic devices, e.g.,
cabinets for and circuit boards in personal
computers and television (TV) sets and vari-
ous other products (electrical cables, switches
and capacitors), building materials, and tex-
tiles (Figure 2). The technical decaBDEs have
the widest industrial use. More details about
the use of PBDEs in various resins or poly-
mers and the applications of these PBDE-
containing resins are given in Tables 4 and 5
in IPCS (2).
The annual world production of flame
retardants is roughly 600,000 metric tons, of
which about 60,000 tons are chlorinated and
150,000 are brominated compounds. Of the
brominated products, about one-third con-
tain tetrabromobisphenol A (TBBP-A) and
derivatives, another third contain various
bromines, including polybrominated
biphenyls (PBBs), and the last third contain
PBDEs (20).
In 1990, global production of PBDE was
40,000 tons per year, of which approximately
10% was commercial penta-, 15% octa-, and
75% decaBDEs (21). The global production
ﬁgures have stayed at approximately the same
levels for more than 10 years, but there has
been a shift in use toward the higher bromi-
nated preparations. Consequently, the use of
Figure 1. General structural formula of PBDEs.
Figure 2. The relative amounts of flame retardants (all
types) used in different sectors. Data from Pijnenburg
et al. (7).
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Table 1. Physical properties for some PBDE congener groups.a
TetraBDE PentaBDE OctaBDE DecaBDE
Chemical formula C12H6OBr4 C12H5OBr5 C12H2OBr8 C12OBr10
Molecular mass 485.8 564.8 801.5 959.2
Vapor pressure (Pa) 2.7–3.3 × 10–4 2.9–7.3 × 10–5 1.2–2.7 × 10–7 <1   × 10–4 (25°C)
(20°C) (20°C) (20°C) 670 (306°C)
Melting point (°C) 79–82 (BDE-47) 92 (BDE-99) ~ 200 290–306
97–98 (BDE-100)
Boiling point (°C) — > 300°C (decompo- — (Decomposition)
sition)
Water solubility (µg/L) — 0.0009 (20°C) — (20–30 ?)
Log Kow 5.9–6.2 6.5–7.0 8.4–8.9 10
— , no information given; ?, unreliable value.
aData from IPCS (2), Sellström (10,11), and OECD (20).
Table 2. Composition of commercial PBDEs.a
Commercial product
Congener group TetraBDEb (%) PentaBDE(%) OctaBDE(%) DecaBDE(%)
Unknown 7.6
TriBDE 0–1
TetraBDEc 41–41.7 24–38
PentaBDEd 44.4–45 50–62
HexaBDEe 6–7 4–8 10–12
HeptaBDEf 43–44
OctaBDE 31–35
NonaBDE 9–11 0.3–3
DecaBDEg 0–1 97–98
aData from IPCS (2). bNo longer commercially produced. cIncluding 2,2’,4,4’-tetrabromodiphenyl ether (BDE-47). dIncluding 2,2’,3,3’,4-
pentabromodiphenyl ether (BDE-82), 2,2’,3,4,4’-pentabromodiphenyl ether (BDE-85), 2,2’,4,4’,5-pentabromodiphenyl ether (BDE-99),
and 2,2’,4,4’,6-pentabromodiphenyl ether (BDE-100). eIncluding 2,2’,4,4’,5,5’-hexabromodiphenyl ether (BDE-153) and 2,2’,4,4’,5,6’-
hexabromodiphenyl ether (BDE-154). fIncluding 2,2’,3,4,4’,5’,6-heptabromodiphenyl ether (BDE-183). gIncluding 2,2’,3,3’,4,4’,5,5’,6,6’-
decabromodiphenyl ether (BDE-209).
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decaBDE today is even more prevalent.
According to IPCS (2), eight manufacturers
of PBDEs are located in the Netherlands,
France, Great Britain, Israel, Japan, and the
United States. In the European Union (EU),
the total import and production of PBDEs
was approximately 11,000 tons in 1989, of
which roughly 4,000 tons were produced
(12). No pentaBDEs are produced in the EU.
In the United States the commercial produc-
tion or import of PBDEs (penta-, octa-, and
decaBDEs) was greater than 1,500 tons per
year during the 1990s (1). 
It is difficult to assess the quantities of
PBDEs used and consumed in different coun-
tries, as the compounds are imported primarily
as additives in manufactured products. For
example, in Sweden the Chemicals Inspectorate
has estimated that in 1993 the import of pure
PBDE chemicals to Sweden was 17 tons.
However, an additional 20 tons were imported
in semimanufactured products. At least 150
tons were supposedly imported in TV sets and
at least the same amount in personal computers
(6). Consequently, the total import of PBDEs
to Sweden was approximately 400 tons per
year, or about 1% of world production.
PBDEs: International and
National Legislation and
Restrictions 
The need for restrictions on certain PBDEs in
different types of plastics and textiles is cur-
rently being discussed within the EU.
Consequently, the use of certain brominated
ﬂame retardants [PBB and tris(2,3-dibromo-
propyl) phosphate] in textiles has already
been banned. Within the EU Existing
Substances Programme, documents are cur-
rently being produced that separately assess
penta-, octa-, and decaBDEs. 
An Organisation for Economic Co-oper-
ation and Development (OECD) document
proposes precautions for each type of PBDEs.
These include recommendations to stop the
use of certain compounds (mainly tetra- and
pentaBDEs), as well as to limit occupational
exposure (20). Also the Paris Commission for
the Prevention of Marine Pollution is work-
ing toward restricting and phasing out
PBDEs and PBBs.
An example of a national restriction is the
Swedish government’s intention to ban
PBDEs and PBBs in products sold on the
Swedish market (22).
PBDEs in the Environment
Sources of PBDEs in the Environment
PBDEs are used as ﬂame retardants in a wide
range of products, and waste from these
products is probably the main source of
PBDEs in the environment. The waste is
either incinerated as municipal waste or
deposited in landﬁlls. Although speciﬁc data
are missing, incineration is thought to be an
important route of release of PBDEs into the
environment. No study on leaching of
PBDEs from landﬁlls is available, but PBDE-
containing products are widespread, and
leaching may be an important long-term
pathway of contamination. PBDEs are dis-
charged into the environment through
sewage, as indicated by analysis of sewage
sludge from various countries. Volatilization
of PBDEs into the surrounding air from elec-
trical components and other products during
their lifetime can also be signiﬁcant. 
Apart from anthropogenic sources, PBDE-
related brominated compounds also appear to
be formed by nature and have been detected
in certain marine sponges (23,24). These
compounds structurally resemble hypothetical
phenolic metabolites of PBDE congeners.
Environmental Levels
PBDEs have been detected in environmental
samples from aquatic environments and
organisms. On a congener basis, the levels of
PBDEs in these samples (such as fatty ﬁshes)
could be similar to those of PCBs, but the
levels of total PBDEs are lower because fewer
congeners of PBDEs are present in technical
mixtures and in the environment. Only a
limited number of PBDE analyses have been
conducted on terrestrial environments. 
Little data are available about the environ-
mental levels of nona-, hepta-, and
hexaBDEs. These compounds probably exist
in the environment at lower concentrations
than other PBDEs, since nona-, hepta-, and
hexaBDEs are impurities of commercial
deca-, octa-, and/or pentaBDE preparations.
The formation of these compounds as a result
of degradation of higher BDs is also possible. 
The following review of environmental lev-
els of PBDEs is a selection of important obser-
vations and is not intended to be a deﬁnitive
listing of all studies performed. For recent
reviews of environmental levels of PBDEs and
other organobrominated compounds, see
de Boer et al. (25) and de Wit (26).
Abiotic samples. Air. In air samples from
the vicinity of recycling plants in Japan and
Taiwan various tri-, tetra-, penta-, and
hexaBDEs were detected in the range of 23–53
pg/m3 (Taiwan) and 7.1–21 pg/m3 (Japan)
(27). In Swedish air samples from remote sites
with no known local source of contamination,
the total PBDE levels were approximately 1–8
pg/m3. Whereas the tetraBDE level was higher
in the gas phase, the pentaBDE level was
higher in the particle fraction, in agreement
with the respective vapor pressures of the two
PBDE homologs (28).
Sewage sludge. PBDEs with 3–7 bromine
atoms were identified in German sewage
sludge samples (29). Pooled samples of
sewage sludge from a Swedish sewage treat-
ment plant (Gothenburg) in 1988 were
found to contain 15 and 19 ng of 2,2´,4,4´-
tetraBDE (BDE-47) and 2,2´,4,4´,5-
pentaBDE (BDE-99) per g ignition loss,
respectively (ignition loss: the carbon content
in sample, measured as the loss in sample
weight after incineration) (30). The sum of
the levels of BDE-47 and BDE-99 were con-
siderably higher, i.e., 100–190 ng/g dry
weight, in recent sludge samples from three
Swedish sewage treatment plants (31). The
Swedish sludge data in Nylund et al. (30)
found a BDE-47+99 level of 21 ng/g, calcu-
lated on dry weight basis. Sellström and co-
workers (31) found that levels of BDE-209
were even higher—160–260 ng/g dry weight. 
Water and sediments. DecaBDE,
octaBDE, or hexaBDE were not found in
water samples taken from more than 200
river, estuarine, and marine waters collected
in Japan in 1977 and 1987–1989 (limit of
detection 0.04–2.5 µg/L) (32). This is proba-
bly due to the very low water solubility of
PBDEs. However, decaBDE, octaBDE,
hexaBDE, pentaBDE, and tetraBDE were
found in samples of river, estuarine, and
marine sediments. DecaBDE was found at
concentrations of < 25–11,600 µg/kg dry
weight, while the range for the other com-
pounds was from below the limit of detection
up to 70 µg/kg sediment dry weight. The
highest concentrations were found in conta-
minated rivers. 
PBDE levels in sediment layers from the
Baltic Sea (Bornholm Deep) decreased with
increasing depth (10,30). At 5 mm deep, the
levels of BDE-47 and BDE-99 were 1.6 and
1.1 µg/kg ignition loss, respectively. Below 40
mm, almost no pentaBDE was detected,
whereas the concentration of tetraBDE was
0.1 µg/kg. In one situation, river samples col-
lected upstream and downstream pinpointed
the PBDE efﬂuent source, a factory manufac-
turing flameproof textiles (14). For the sum
of the three congeners BDE-47, BDE-99,
and 2,2´,4,4´,6-pentaBDE (BDE-100), the
concentration in sediment varied from below
detection to 120 ng/g ignition loss, whereas
BDE-209 (the full-brominated congener) had
a peak concentration of 12,000 ng/g. In addi-
tion, the peak concentration of another
brominated flame retardant, hexabromocy-
clododecane (HBCD), was 7,000 ng/g igni-
tion loss. All three analyzed compounds or
compound groups had the highest levels at
the same sampling location.
Analysis of sediments from a number of
European estuaries revealed high concentra-
tions of BDE-209 in some rivers in the
United Kingdom (e.g., River Mersey, 1,700
ng/g dry weight) and Belgium (River Schelde,
200 ng/g dry weight), whereas most samples
showed levels below 20 ng/g dry weight (31).
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BDE-47+99 levels were always considerably
lower than those of BDE-209. 
Biota. Aquatic organisms. In 1981, fish
from the Swedish River Viskan were analyzed
for PBDEs (33). The maximum levels in pike
were 27 mg/kg lipid in muscle and 110
mg/kg lipid in liver. The water system was at
that time receiving efﬂuent water from nearby
textile factories. Later analysis of PBDEs and
HBCD in fish from the River Viskan indi-
cated lower PBDE levels (maximum PBDE
levels 4.6 mg/kg lipid; sum of BDE-47,
BDE-99, and BDE-100) (14). Concomitant
analysis of sediment samples showed that
tetra- to pentaBDEs and HBCD are much
more bioavailable than the full-brominated
BDE-209. 
A number of species from Swedish fauna
were analyzed for the presence of PBDEs (sum
of BDE-47, BDE-99, and BDE-100) from
1979 to 1988 [(34–36); Table 3]. The highest
levels were found in fish from waters with
known or suspected local sources of contami-
nation. However, fish from other sampling
spots also contained measurable levels. It is evi-
dent that animals (herring and seal) from the
Baltic Sea contain higher levels of PBDEs than
the same or similar species from other waters. 
Herring collected during 1985 from three
North Sea regions and from the Straits of
Dover (between Holland and United
Kingdom) contained an average of 8.4–100
µg BDE-47/kg lipid. Eels from Dutch rivers
and lakes (10 locations) contained from < 20
to 1,700 µg BDE-47/kg lipid (37).
Freshwater fish of various species from the
waters of North-Rhine Westfalia contained
18–983 µg PBDE/kg lipid, and Baltic and
North Sea ﬁsh 12–57 and 1–120 µg/kg lipid,
respectively, quantified with Bromkal 70-
5DE as a reference (38). In ﬁsh and shellﬁsh
samples from Osaka Bay, Japan, measurable
levels of PBDEs were occasionally found
(32). Concentrations ranging from 0.1–14.6
µg/kg wet weight were observed for tetra-,
penta-, hexa-, and decaBDE, respectively.
PBDEs were detected in bottlenose dolphins
at levels up to 8 mg/kg lipid (39). PBDEs
have also been found in the blubber of pilot
whales caught off the coast of the Faroe
Islands from 1994 to 1996 (40). Nineteen
tetra- to hexaBDEs were identified in the
pilot whales at mean total levels of about 1–3
mg/kg lipid, depending on sex and age.
BDE-47 and BDE-99 accounted for about
70% of total PBDEs. 
Haglund and co-workers (13) reported
PBDE levels in fish and seals caught in the
Baltic Sea. In herring (different age groups)
and in salmon muscle, the BDE-47 levels
were 3.2–27 and 167 µg/kg lipid weight,
respectively. These BDE values in herring are
lower than those earlier analyzed by Janssson
and Sellström and their co-workers (35,36).
PBDEs and other organohalogen compounds
were found in sea-run Baltic salmon from the
River Dalälven (total PBDE levels about 300
µg/kg lipid) (41). The presence of methylated
and phenolic PBDE derivates at levels similar
to those of the major PBDE congeners was
also reported (13,41). Strandman and co-
workers (42) showed that the total PBDE
(BDE-47, BDE-99, BDE-153) levels in Baltic
herring were 13–24 µg/kg lipid weight and in
sprat 22–149 µg/kg lipid weight. In this
study, analysis of different age groups of Baltic
fish suggests an age-related accumulation of
PBDEs in the body fat (Figure 3). PBDE con-
centrations (sum of BDE-47, BDE-99, and
BDE-153) showed an age-related increase in
1- to 3-year-old Baltic herring, as well as in 3-
to 13-year-old sprat (42). In sprat, the accu-
mulation seemed to level off at 8 years of age.
Also, Haglund et al. (13) found an age-related
PBDE uptake (Figure 3).
Recent studies from the American conti-
nent have shown relatively high levels of
PBDEs in certain samples from the aquatic
environment. Canadian samples of crab, ﬁsh,
and marine mammals all contained PBDEs,
and the highest levels were found in porpoise
from British Columbia waters (peak value,
1,400 µg BDE-47/kg lipid) (43). PBDE levels
in ﬁsh from the Great Lakes were analyzed in
two studies. One study (44) found total PBDE
levels of 135–545 µg/kg lipid in Great Lakes
lake trout, and the other (45) found about
3,000 µg PBDE/kg lipid in Lake Michigan
steelhead trout. On a wet weight basis, the
Lake Michigan ﬁsh contained almost 6 times
more PBDE (41 µg/kg wet weight) than the
Baltic salmon (7 µg/kg fresh weight).
Terrestrial/avian organisms. The osprey
(Pandion haliaetus), a bird that feeds exclu-
sively on fish, is the only nonaquatic species
listed in Table 3 that has relatively high PBDE
levels (36). In addition, eggs from the ﬁsh-eat-
ing guillemot contain relatively high levels of
PBDEs. Apart from these species, samples
from all other nonaquatic avian or terrestrial
wild-living species (e.g., moose, reindeer)
showed low or nondetectable PBDE levels.
Trend Studies
Time trend. A retrospective time trend of
PBDE levels was constructed (10,46) through
laminated sediment cores collected in the
Bornholm Deep (southern part of the Baltic
Proper). In contrast to other environmental
pollutants such as PCBs and DDT, PBDEs
Table 3. Swedish PBDE levels in sediment and biota, 1979–1988.a
No. of 2,2’,4,4’- 2,2’,4,4’,5- Unknown Sampling
Sample samplesb tetraBDEc pentaBDEb pentaBDEb year
Aquatic organismsd
Whiteﬁsh, freshwater 35 15 7.2 3.9 1986
Arctic char, Lake Vättern 15 400 64 51 1987
Herring, Skagerrack 100 59 9.8 4.7 1987 (April) 
Herring, Baltic proper 60 450 46 32 1987 (June)
Herring, Baltic proper 10 (in) 38 17 6 1987 (Sept)
Herring, Bothnian Sea 100 82 27 14 1986 (Nov) 
Bream, River Viskanc 2 (in) 250, 750 2.3, 2.4 11, 37 1987
Perch, River Viskanc 2 (in) 2,200  380 230 1987
24 000 9,400 3500
Pike, River Viskanc 2 (in) 2,000  78, 170 1987
6 500 1,100 640
Pike, Dalsland Canal 9 (2 x p) 94–98 60–74 25–36 1988
Trout, Dalsland Canal 22 (in, p) 120–460 64–590 37–150 1988
Grey seal, Baltic Sea 8 (p) 650 40 38 1979–1985
Ringed seal, Svalbard 7 (p) 47 1.7 2.3 1981
Terrestrial/avian organismsd
Rabbit 15 (p) < 1.8 < 0.3 < 0.2 1986
Moose 13 (p) 0.8 0.6 0.2 1985–1986
Reindeer 31 (p) 0.2 0.3 < 0.1 1986
Starling, young 4 (in) 2.7–7.8 2.3–4.2 0.6–1.1 1988
Osprey 35 (p) 1,800 140 200 1982–1986
Abbreviations: p, pooled sample; in, individual sample.
aData from Jansson et al. (34,35) and Sellström (36). bConcentrations in µg/kg lipid weight (sediment: µg/kg ignition loss). cEfﬂuents
from industry using ﬂame retardants reach the Viskan-Häggån river systems.. dMuscle samples taken for analysis, except for reindeer
(suet) and seal (blubber).
Figure 3. Age-related accumulation of PBDEs (sum of
BDE-47, -99 and -153) in Baltic herring and sprat. Data
from pooled sample analyses in Haglund et al. (13) and
Strandman et al. (42).
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were detected quite late in the cores, but from
the late 1970s on, the levels increased exponen-
tially (Figure 4). This strong increase in PBDE
levels has continued to the most recent part of
the study (1988–1989). This is in contrast to
other environmental contaminants, the levels of
which have decreased or remained unaltered in
newly formed sediment layers (47). 
The total concentrations of BDE-47,
BDE-99, and an unidentified PBDE in
guillemot eggs (from Stora Karlsö in the
Baltic Sea) increased from 158 µg/kg lipid in
1970 to 1,211 µg/kg lipid in 1989 (36,48).
However, subsequent egg analyses suggest a
somewhat decreasing trend from 1990 and
later (11). The trend analysis is hampered by
large annual variations in PBDE concentra-
tions, which may be explained in part by the
small number of eggs (n = 10) collected per
year (10). Concentrations of another bromi-
nated ﬂame retardant, HBCD, increased sig-
nificantly in the eggs over the entire time
period (1968–1997) (49).
Studies using sample-bank specimens of
pike muscle from fish in Lake Bolmen in
southern Sweden showed increasing concen-
trations of PBDEs from 1974 to 1991 (from
about 10 to 100 ng BDE-47/g lipid) (10).
Since 1991, the trend in PBDE levels in pike
is more difﬁcult to interpret but seems stag-
nant (49). Levels of the methoxylated deriva-
tive of BDE-47 (MeO-BDE-47) decreased in
in pike during the time period (49).
Eel samples from the Rhine and Meuse
Rivers revealed decreasing PBDE time trends
levels during 1983–1993, whereas PBDE lev-
els increased in the River Roer eel during the
same time period (37,50).
Thus, time trend studies during the 1970s
and 1980s show that PBDE levels in biota
generally differ from those of most other
organohalogenated environmental chemicals:
PBDE levels increase or remain constant,
whereas levels of most other persistent com-
pounds decrease. Time trends in recent years
are often difficult to follow because of small
amount of samples and/or lack of data. 
In addition to environmental samples,
mothers’ milk has shown a strong increase in
PBDE levels during 1972–1996 (51) (Figure
5) (see “Human Exposure to PBDEs”).
Spatial trend. Few studies have been
designed to study spatial or regional trends in
environmental occurrence of PBDEs.
However, de Boer (52) studied levels of
BDE-47 in livers of cod caught from various
locations in the North Sea. A distinct spatial
trend was observed, with decreasing levels
from the southern to the northern part of the
North Sea (southern NS; 170 µg/kg, central
NS; 54 µg/kg;; northern NS, 26 µg/kg; mean
values, all on wet weight basis). Other
organohalogenated compounds such as
sumDDT, exhibited the same type of spatial
patterns. In the same study, the levels of
BDE-47, the PBDE congener found at high-
est concentrations, remained at a relatively
constant level during the period of sample
collection. This trend was different from
those of several organochlorine compounds
that, with the exception of DDT, showed
decreasing time trends in the same samples.
Bioaccumulation and Biomagniﬁcation
Although limited data are available, existing
information strongly suggests that PBDEs are
globally transported and distributed in the
environment in a manner similar to PCBs.
Consequently, they are probably of minor
importance in terrestrial systems but may
reach levels of concern in aquatic environ-
ments. In addition, PBDEs are persistent and
have very low water solubility, high binding
affinity to particles, and tendencies to accu-
mulate in sediments. The presence of PBDEs
in biota is likely to be because of their high
lipophilicity and resistance to degradation. 
Available data indicate that the higher
brominated compounds (heptaBDEs and
above) do not bioaccumulate to a signiﬁcant
degree, possibly because of a low uptake in
organisms. However, in experimental studies
the observation time may have been too short
to detect a slow uptake. The uptake of the
lower brominated PBDEs in the biota is more
signiﬁcant. 
Increasing levels of the full-brominated
BDE-209 were observed in rainbow trout
during dietary exposure to this congener (53).
Exposure of rainbow trout under static condi-
tions to BDE-209 in water, however, did not
result in measurable concentrations in mus-
cle, skin, or viscera after 48 hr (54). The very
low solubility of BDE-209 in water makes
the latter study of questionable relevance.
Bioconcentration factors of < 4 for BDE-209,
< 2 for octaBDE, < 4 for heptaBDE, and < 4
for hexaBDE were determined in a bioaccu-
mulation study in carps exposed to a mixture
of hexa-, hepta-, nona-, and decaBDE for 8
weeks (probably present in the water) (55). In
contrast, a bioconcentration factor of
> 10.000 was found in a study with carp
exposed to 10 or 100 µg pentaBDE/L for 8
weeks (probably a commercial mixture, i.e., a
mixture of a tetraBDE and two pentaBDE
congeners) (55). Also, components of com-
mercial “tetraBDE” (41% BDE-47; 45%
BDE-99, 7% hexa- and 7–8% unknown
PBDEs) are considered accumulative (6). An
inverse relation was shown between the
uptake efficiency and number of bromine
atoms in pike when tetra (BDE-47), penta
(BDE-99), and hexa (BDE-153) congeners
were studied (56). The uptake efficiency of
BDE-47 was over 90% and thus the highest
of all the studied organohalogens.
Comparison of PBDE concentrations at
different trophic levels of aquatic ecosystem
suggests that PBDEs have a biomagniﬁcation
potential in the food chain. PBDE levels in
Baltic herring, salmon, and seals (13), and
those in guillemot eggs and osprey (36) are
highly indicative of biomagnification in the
Baltic ecosystem (Figure 6). In a recent study,
Burreau et al. (57) calculated biomagniﬁcation
potentials for a number of PBDE congeners
on the basis of sprat, herring, and salmon
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Figure 4. Time trend study of a laminated sediment core
from the Baltic Sea (Bornholm Deep). Data from Nylund
et al. (30).
Figure 5. Time trend of the sum concentrations of 8
PBDE congeners in pooled mother’s milk samples from
Swedish mothers living in the Stockholm region. Data
from Norén and Meironyté (51).
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Figure 6. Concentration of the most abundant PBDE
congener, BDE-47, at different trophic levels of the
Baltic food chain: Baltic herring (muscle), salmon (mus-
cle), ringed seal (blubber) and grey seal (blubber) (13), as
well as guillemot (egg) and osprey (muscle) (36).
Samples were collected between 1981 and 1991 along
the Swedish coastline of the Baltic. The value for guille-
mot eggs prepresents the mean of six different analyses
from 1982 to 1989. 
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data. All PBDE congeners analyzed were bio-
magnified. The tetra- and pentaBDEs were
biomagnified to approximately the same
degree, the triBDEs slightly less and the
hexaBDEs considerably less. Preliminary data
indicate that the tri-, tetra- and pentaBDEs
are biomagnified more efficiently than any
PCB congener. 
It can be concluded, therefore, that
PBDEs bioaccumulate in biota and that the
extent of accumulation is inversely related to
the degree of bromination. Available data
indicate biomagnification of PBDEs in the
food chain.
Environmental Transformation
Small amounts of data are available on trans-
formation of PBDEs in the environment.
Most studies have been done with decaBDE
and mono/diBDEs.
Incineration. Incineration of waste con-
taining PBDEs may result in formation of
PBDDs and PBDFs (17,18). These com-
pounds are structurally similar to the corre-
sponding chlorinated compounds, more toxic
than PBDEs, and very persistent in the envi-
ronment. Formation of these compounds
depends largely on combustion conditions. In
a modern waste incinerator with well-
controlled burning conditions, emission of
brominated dioxins and furans is very low. In
a Swedish study (58) on incinerator plants
with well-controlled combustion conditions
and efficient flue gas cleaning, no unaccept-
able environmental risk was found to be asso-
ciated with combustion of PBDE-containing
materials. On the other hand, uncontrolled
ﬁres at waste disposal sites may lead to forma-
tion and release of PBDDs and PBDFs into
the environment (2).
Photodegradation.  Watanabe and
Satsukawa (59) showed that debromination
of decaBDE, dissolved in organic solvents,
occurs in ultraviolet (UV) light and sunlight,
leading to formation of lower brominated
BDEs and various PBDFs with 1–6 bromine
atoms. Formation of PBDFs seems to
occur only from low-brominated diphenyl
ethers, but not directly from decaBDE.
Photodegradation of decaBDE dissolved in
water was also shown to occur, but no lower-
brominated diphenyl ethers were detected
among the degradation products (54,60).
Sellström and co-workers (61) studied the
photodegradation of decaBDE in various
matrices (toluene, silica gel, sand, soil, and
sediment). They showed that the time course
for decaBDE debromination and formation/
debromination of lower-brominated diphenyl
ethers was rapid in toluene, whereas the
degradation process in other matrices was
considerably slower (half-life of decaBDE
exposed to UV light in toluene and sand was
15 min and 12 hr, respectively).
Microbiologic degradation. No biotrans-
formation products of BDE-209 were
detected in sediment samples after incubation
for 4 months (6). For other flame-retardant
PBDEs, no data are available. On the other
hand, low-brominated diphenyl ethers, not
used as ﬂame retardants, are more likely to be
biodegradable. Microbiologic degradation of
mono- and diBDEs has been demonstrated,
but these congeners were not used as a carbon
source for the bacteria (62–64). Even though
BDEs with less than four bromine atoms are
not used as ﬂame retardants, they have been
detected in the environment, possibly a result
of degradation of higher-brominated diphenyl
ethers (DEs). Thus, on the basis of limited
data, microbial degradation of PBDEs seems
to depend on the degree of bromination, and
the full-brominated congener seems to be
resistant to microbial degradation. 
PBDEs in the Environment: Summary
and Conclusions
PBDEs have been detected in air samples, even
from remote areas. Analyses of organisms from
terrestrial ecosystems indicate low levels of
PBDEs but considerably higher levels are
found in aquatic environments. In sediments
the higher-brominated compounds are preva-
lent, but in biota these congeners are normally
below the limit of detection. This indicates
that the bioaccumulation of highly brominated
PBDEs (especially decaBDE) is low. Microbial
degradation of decaPBDE is negligible,
whereas photodegradation of decaBDE may
generate lower-brominated PBDEs. Thus, the
lower brominated PBDEs, tetraBDEs, and
pentaBDEs predominate and accumulate in
biota. The uptake effieciency of BDE-47 in
fish is very high, but an increase in PBDE
bromination will gradually decrease uptake.
Accumulation of PBDEs in ﬁsh appears to be
age-related. The highest concentrations are
found in top predators of aquatic ecosystems,
suggesting the biomagnification potential of
these compounds. Tetra- to hexaBDEs are
probably the principal congeners to which
humans are exposed via food. On a congener
basis, the levels of PBDEs in these samples
could be similar to those of the more frequent
PCB congeners, but because fewer congeners
are present, total PBDE levels are lower than
total PCB levels. Observed spatial differences
in environmental PBDE levels may reflect
emissions from regional or point sources.
Series of samples from sediments, guillemot
eggs from the Baltic, and banked samples of
pike from a Swedish lake have been used for
time-trend analyses of PBDE levels. Until the
late 1980s, PBDE levels in both sediment and
biota generally showed an increasing trend.
However, the most recent biologic samples
(1990 and onward) indicate somewhat lower
PBDE levels, although the variation is large.
Thus, continuation of the time trend studies
is important.
Human Exposure to PBDEs
As pointed out previously, the environmental
fate of PBDEs appears similar to the fate of
other persistent environmental pollutants,
PCBs, for example. On the basis of several
years of PCB monitoring, it has been estab-
lished that the main route of human exposure
to PCBs is via food. Food of animal origin
with high fat content, e.g., fatty fish, meat,
and dairy products are major contributors to
dietary exposure. Because of the similarity
between PCBs and PBDEs in their environ-
mental distribution, attention also should be
focused on these food items when assessing
exposure to PBDEs. For another persistent
organic pollutant, 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD), as much as 98% of human
exposure is suspected to occur through con-
sumption of foods of animal origin (65).
However, until recently very few estimates of
human dietary PBDE intake have been made.
In addition, little is known of other routes of
human exposure and their importance in total
human exposure to PBDEs. 
PBDE Levels in Food
Fish. Several fish species consumed by man
have been analyzed for PBDEs. Large variations
in PBDE levels observed in freshwater ﬁsh may
result from widely varying degrees of contami-
nation. PBDE levels in ﬁsh sampled in Swedish
lakes and rivers (pike, perch, bream, and trout)
varied from 26 to 36,900 µg/kg lipid
(14,33,36). In German freshwater ﬁsh, the lev-
els varied between 18 and 983 µg/kg fat (2,38),
and in eel from Dutch waters the variation in
BDE-47 levels was < 20–1,700 µg/kg lipid
(52). Herring (North Sea, Baltic Sea), salmon
(Baltic Sea), and cod liver (North Sea) have
been analyzed in studies of marine and brack-
ish-water ﬁsh (13,36,37,41,52). Baltic herring
contained 24–528 µg/kg lipid, whereas
Swedish west coast herring contained 17–74
µg/kg lipid (Swedish herring analyses: sum of
three congeners) and the North Sea herring
9–100 µg BDE-47/kg lipid (36,37). Levels in
Baltic herring are generally higher than those in
Atlantic herring. A similar difference was
shown earlier for PCBs (66), which reflects,
among other things, the limited water exchange
between this inland sea and the ocean. 
Dairy products. PBDE levels of 2.5–4.5
µg/kg milk fat, determined to be Bromkal 70-
5DE, have been reported in cows’ milk in
Germany (38). Levels in mixed dairy products
from 1999 Swedish market basket samples
(sum of levels of BDE-47, -99, -100, -153,
and -154), however, are considerably lower,
with a mean value of 0.36 µg/kg milk fat (67).
Mothers’ milk. PBDE levels in mothers’
milk have been studied in a survey of 25
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German mothers (38). Levels varied between
0.6–11 µg/kg (i.e., 600–1,100 ng/kg) milk fat. 
Darnerud and co-workers (68) studied 39
primiparous women from Uppsala county,
Sweden, and analyzed the five most fre-
quently found PBDE congeners in their milk
(BDE-47, -99, -100, -153, and -154). The
mean value was 4.4 µg/kg lipid and the range
1.1–28.2 µg/kg. Milk PBDE levels correlated
positively and significantly with mothers’
smoking habits and body mass index.
However, no correlation was seen between
PBDE and mothers’ ages, consumption of
ﬁsh, places of residence during childhood or
adulthood, birth weights, or frequency of
using computers.
In another Swedish study, a time trend was
created using stored samples of breast milk col-
lected from 1972 to 1997 (51). The mean
PBDE level (sum of eight different congeners;
predominantly BDE-47) in milk from 1997
was 4 µg/kg, quite similar to the above report
by Darnerud et al. (68). Concentrations of
PBDEs in milk showed a strong time-depen-
dent increase, with a doubling in levels within
5 years (Figure 4). In contrast, tissue levels of
most halogenated aromatic hydrocarbons of
concern (e.g., PCB, DDT) were declining.
Thus, future levels of PBDE in milk may
eclipse those of PCB if trends continue.
PBDE levels detected in mothers’ milk
are, on a lipid basis, generally within the same
range as those observed in human adipose tis-
sue samples from the United States and
human serum samples from Sweden (see
“PBDE Levels in Humans”). 
PBDEs from other food groups. Except for
the low levels of PBDEs found in samples
from animals living in the wild (36) (Table 3),
little data are available on PBDE levels in meat
and eggs. However, preliminary data from
mixed meat products from Sweden (market-
basket samples) revealed a mean level of 0.36
µg/kg fat (67). The mean level in Swedish eggs
(from the same study) was 0.42 µg/kg fat. 
Estimation of PBDE Exposure
From food. Darnerud et al. (69), using primar-
ily Nordic data, estimated the exposure of
PBDEs from food in a report to the Nordic
Council of Ministers (69). Their estimates were
based on the upper range of total PBDE levels
in herring caught in the Baltic Sea (36), i.e.,
528 µg/kg lipid (of which 450 µg/kg was BDE-
47 and the remainder two pentaBDEs). The
total PBDE intake can be estimated by assum-
ing a similar relative intake from different
dietary sources, as described earlier in a Swedish
estimation for PCBs (66). Consequently,
according to this very approximate calculation,
the total PBDE intake for the Nordic con-
sumer would be 0.2–0.7 µg/day. 
A Swedish intake estimate was made
recently (67) on the basis of PBDE levels
(BDE-47, -99, -100, -153, and -154) in mar-
ket basket samples from 1999. Provisions
from eight grocers in four major Swedish
cities were received and divided into selected
groups. Within these groups, each food item
was added in an amount determined from per
capita consumption statistics. Analyses of the
homogenates were performed and sumPBDE
levels were obtained by addition of congener
levels, assuming that levels below the limit of
quantiﬁcation (LOQ) were equal to one-half
of this limit. The total PBDE intake was
obtained by adding intake from the fish,
meat, dairy products, eggs, fats/oils, and pas-
try food groups (i.e., the product groups
assumed to contribute most to total intake).
Using this method, total PBDE intake in
Sweden was estimated to be 51 ng/day.
Almost half total intake originated from ﬁsh
products; meat, dairy products, and fat/oils
contributed approximately 15% each. Total
PBDE intake was 4–14 times below estimates
performed earlier but should be a more accu-
rate description of the intake, as it is based of
a more complete set of occurrence-level data.
However, this estimate should be supple-
mented by studies from other countries and
by using other methods of estimating intake
to obtain a more complete picture of the
intake of PBDEs from food. 
From mothers’ milk. The most recent
human milk data come from two Swedish
surveys (51,68). The mean PBDE levels in
these two studies are almost identical, giving a
total mean value of 4.2 µg/kg milk fat. To
estimate the PBDE intake in infants, con-
sumption data from Ahlborg and co-workers
(70) were used. The calculated PBDE intake
using these predictions (3.7% fat in milk;
consumption of 0.7 L milk daily for 6
months) is 0.11 µg/day from mothers’ milk,
or 20 µg in 6 months.
Other possible routes of exposure. It
appears obvious that sources other than food
significantly influence total PBDE intake in
humans. There is, however, almost a complete
lack of data on these other sources of human
exposure. Emission of PBDEs from electronic
apparatuses like computers and TV sets, espe-
cially from warm devices after prolonged use,
are suspected. In an experiment with a TV set,
Ball et al. (71) detected PBDEs in air drawn
from a warm TV. In Darnerud’s previously
cited study (68) on PBDE milk levels from
primiparous women, however, no correlation
was found between frequency of computer
usage and PBDE milk levels. Because of these
conﬂicting results, the use of computers and
TV sets as sources for human exposure should
be further investigated.
Sjödin et al. (72), in a recent publication,
monitored the occupational exposure to
PBDEs. Subjects working at a Swedish dis-
mantling plant had signiﬁcantly higher serum
levels of all studied PBDE congeners com-
pared to both hospital cleaners and office
clerks using computers (see “PBDE Levels in
Humans”). It was concluded that exposure
from daily computer work in an office does
not appear to increase serum PBDE levels. 
PBDE Levels in Humans
PBDEs were detected (up to 5 µg/kg dry
weight) in 2 of 40 hair samples from American
citizens living in an area where PBDEs are
manufactured, according to DeCarlo (73).
In two studies from the United States
(74,75), PBDEs were detected in human adi-
pose tissue samples collected in 1987. The
presence of PBDEs was demonstrated in all
samples (48 composite samples from 865
individuals). These studies also showed a
large variation in PBDE levels between indi-
viduals (hexaBDE, not detected–1 µg/kg
lipid; heptaBDE, 3 ng–2 µg/kg lipid;
octaBDE, not detected–8 µg/kg fat; no con-
gener speciﬁcation was presented). 
PBDE levels in adipose tissue were
reported in three Swedish studies. In a male
Swede 74 years of age, a level of 8.8 µg BDE-
47/kg lipid was reported (13). In the second
study (76), adipose tissue from 77 individuals
of both sexes, 28–85 years of age, some of
whom were cancer patients, were analyzed. In
persons without malignancies, the mean BDE-
47 level was 5.1 µg/kg lipid, but in patients
with non-Hodgkin lymphoma (NHL) it was
13 µg/kg lipid. (According to the authors a
connection between PBDEs and NHL cannot
be excluded.) In the third Swedish study, levels
of several PBDEs in adipose and hepatic tissue
from two male subjects (66 and 78 years of
age) were reported (77). The mean levels of
BDE-47 in these two types of tissue were 2
and 2–5 µg/kg lipid, respectively. In a Finnish
study (42), the PBDE levels (sum of BDE-74,
-99, and -153) in adipose tissue from ran-
domly selected individuals (36-84 years of age)
ranged from 6.2 to 22 µg/kg lipid. 
Studies on human blood have demon-
strated that 2,2´,4,4´-tetraBDE is the major
PBDE congener (of six congeners analyzed)
in serum samples from Swedish blood donors
(n = 40; sampling year 1996) (78). The mean
serum level of sumPBDE was 2.1 ± 1.4 µg/kg
lipid, which is approximately two orders of
magnitude lower than that of sumPCBs. 
Results from analysis of PBDEs in Swedish
breast milk are presented above (“PBDE Levels
in Food”) (51,68). PBDE levels in lipids are in
the same range as those for adipose tissue and
blood from Swedish individuals.
In a study on Swedish dismantling plant
workers, levels of five PBDE congeners
[BDE-47, BDE-153, BDE-154, BDE-183
(2,2´,3,4,4´,5´,6-heptaBDE), and BDE-209]
were measured in serum (72). Among the
dismantling workers heptaBDE congener
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BDE-183 was the most abundant at the
mean concentration of 8 µg/kg lipid, and also
the mean concentration of BDE-209 was as
high as 5 µg/kg lipid. The sumPBDE levels in
groups of hospital cleaners, computer clerks,
and electronics dismantlers were 3, 4, and 26
µg/kg lipid weight, respectively. Therefore,
occupational exposure in dismantling plants
may contribute signiﬁcantly to human expo-
sure to PBDEs. Nevertheless, PBDE levels of
the dismantling workers are still rather low
compared to PCB serum levels (26 µg
sumPBDE and 270 µg PCB-153 per kg lipid,
respectively).
Human Exposure to PBDEs: Summary
and Conclusions
Sufficient data are available on PBDE levels
in fish, whereas less is known about PBDE
levels in other major food groups or about
possible differences in food levels between
countries or regions. 
A recent intake study based on a complete
set of Swedish occurrence (market basket)
data from 1999 found PBDE intake from
food to be 51 ng/day. The intake from moth-
ers’ milk during lactation, using data from
Swedish studies, was estimated to be 110
ng/day. These estimates should be supple-
mented by studies from other countries and
by using other methods to estimate intake to
obtain a more complete picture of the intake
of PBDEs from food. 
Analytic data on human blood, adipose
tissue, and milk have conﬁrmed that PBDEs
are also present in the human body. The
major route of human exposure appears to be
via food, although other routes of exposure
cannot be excluded. Workers exposed to
PBDEs during computer dismantling were
shown to have signiﬁcantly higher blood lev-
els of several PBDE congeners than nonex-
posed subjects. Available data generally
suggest that current levels of PBDE are more
than an order of magnitude lower than those
of PCBs. However, attention must be paid to
exposure of infants from continously increas-
ing levels of PBDEs in mothers’ milk. 
Toxicokinetics 
Experimental Animals
Absorption and elimination/retention. Oral
administration of 14C-labeled decaBDE
(BDE-209) to rats resulted in fecal excretion
of > 90% of the dose 2 days after administra-
tion. Elimination in urine and in expired air
was less than 1% over a period of 16 days,
and accessible data seem to suggest minimal
absorption of decaBDE from the gastroin-
testinal tract (54,60,79). In a carcinogenicity
study (80), 14C-labeled decaBDE was given
in the diet to rats to quantify decaBDE
absorption from the gastrointestinal tract.
Results indicated that for all dose levels
(250–50,000 mg/kg) more than 99% of the
radioactivity recovered was eliminated in the
feces within 72 hr. Urinary excretion
accounted for about 0.01% or less of the
dose; tissue levels of radioactivity were near
the limit of detection, and in the liver, the
radioactivity was confirmed as decaBDE.
Similarly, El Dareer and co-workers (81)
showed that < 1% of the dose of a radiola-
beled decaBDE given orally to rats was found
in tissues (about half in the liver) after 24 hr.
In a 2-year accumulation study, rats were
maintained on diets providing up to approxi-
mately 1.0 mg technical decaBDE/kg body
weight (bw) per day (of which 77.4% was the
decaBDE congener, 21.8% nonaBDE, and
0.8% octaBDE). Selected tissues were analyzed
for total bromine content. In most tissues
(serum, liver, kidneys, skeletal muscle, and
testes) the bromine contents were not above
background, but in the adipose tissue bromine
concentration was 3-fold that of controls (0.1
mg/kg bw/day). Regarding elimination, the
moderate bromine accumulation in the adi-
pose tissue remained unaffected during 90 days
of recovery, whereas bromine was cleared from
the liver within 10 days of recovery (82,83). 
These data suggest that the bioaccumula-
tion potential of decaBDE is low, but the
retention in body fat may be pronounced. In
comparison, the bioaccumulation of an
octabromobiphenyl (belonging to the PBB
group) was much more pronounced (79).
Possible metabolism and/or debromination of
decaBDE may interfere with the results.
Von Meyerink and co-workers (84) stud-
ied the retention of different fractions of
Bromkal 70 in perirenal fat from rats. Bromkal
70 (mainly pentaBDE) was given as a single
oral dose of 300 mg/kg bw, and the rats were
killed after 1–10 weeks. Concentrations of the
different PBDEs were analyzed by high pres-
sure liquid chromatography, and gas chro-
matography–mass spectroscopy was used to
conﬁrm the degree of bromination (the stereo-
chemistry of the individual compounds was
not elucidated). Half-lives for two hexaBDE
congeners were 50 and 105 days, respectively,
and for two different penta congeners, 42 and
25 days. Half-life of tetraBDE(s) was 19–30
days, depending on sex of the subject. Half-life
was shorter in males than in females.
In a bioaccumulation study in pike (Esox
lucius) (56), 12 different halogenated diaro-
matic compounds, including three PBDE
congeners, were administered in feed.
Gastrointestinal bioavailability was 95% for
BDE-47 (highest for all compounds studied),
60% for BDE-99, and 40% for BDE-153,
indicating a clear decrease in uptake with
increasing bromination. 
Generally, lower-brominated PBDEs
appear to be accumulated in biota to a greater
extent than higher-brominated compounds.
This is also evident from comparison of the
Bromkal 70-5DE composition with the PBDE
pattern in herring and seal: concentrations of
tetraBDE (BDE-47) are increased in biota in
relation to other congeners. Conversely, the
relative concentrations were the same in
Bromkal 70-5DE and in samples from herbiv-
orous mammals in Sweden. According to
Zitko (85), compounds with low bromine
content are bioconcentrated more strongly
from water than compounds with high
bromine content. For example, PBBs with
more than six bromine atoms were scarcely
bioconcentrated; similar conditions may apply
for PBDEs. In contrast, half-lives of PBDEs in
adipose tissue of rats increase with the degree
of bromination (84). It can be concluded that
absorption of PBDEs, which favors lower-
brominated congener groups, is an important
determinant of bioaccumulation, at least in
aquatic environments. Elimination of PBDE,
on the other hand, may be slower for higher-
brominated compounds, although they are less
accumulative. However, data are sparse and
somewhat contradictory.
Distribution. Tissue distribution of 14C-
decaBDE was studied in rats 16 days after a
single oral dose (54,60,79). Radioactivity was
observed only in the adrenal glands (0.01%
of administered dose) and in the spleen
(0.06% of administered dose) but not in any
other tissue studied.
In the above-mentioned high-dose experi-
ment with oral 14C-decaBDE (80), the liver
contained about 0.5 and 0.016% of the dose
24 and 72 hr, respectively, after dosing.
Radioactivity extracted from the liver was
found to be mainly the unchanged compo-
nent. Traces of the label were found in the
kidneys, spleen, lung, brain, muscle, fat, and
skin. Distribution data after intravenous (iv)
injection of labeled decaBDE indicate that
feces collected during this period and the
contents of the intestines altogether contained
74% of the dose, suggesting considerable bil-
iary excretion. Radioactivity was also detected
in the liver, kidneys, and lungs, and at lower
concentrations in muscle, skin, and fat. 
In a comparative study on radiolabeled
BDE-47 in rats and mice (12,16), an effective
absorption and accumulation in adipose tis-
sue was shown. The study also indicated a
marked species difference in degree of reten-
tion. In rats 86% of the oral dose (approxi-
mately 30 µmol/kg bw=14.6 mg/kg bw) was
retained in the body within 5 days, compared
to only 47% in mice. Radioactivity was about
3 times higher in fat than in liver in rats,
whereas in mice the levels in the two tissues
were comparable. 
Metabolism. In studies by Norris and co-
workers (54,60,79), rats were injected iv with
14C- decaBDE, after which the radioactive
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compounds in feces were analyzed. Of the
excreted fecal label, 63% were unidentified
metabolite(s) of decaBDE and 37% were
unchanged decaBDE. El Dareer and co-
workers (81) obtained similar results. They
suggested that extensive metabolism of the
orally administered compound might take
place in the gastrointestinal tract.
Studies with 14C-BDE-47 in rats and mice
revealed ﬁve hydroxylated PBDE metabolites
in feces and tissues, although BDE-47 was the
major compound detected (12,16). A marked
difference was found in urinary excretion
between the mouse and rat. Within 5 days,
rats excreted < 1% and mice excreted 33% of
the dose in urine (the corresponding ﬁgures for
fecal excretion, including nonabsorbed mater-
ial, were 14 and 20%, respectively). The label
in the mouse urine was highly hydrophilic and
labile, and no specific metabolites could be
identified. No debromination products of
PBDEs were found. Thus, the metabolism of
BDE-47 seems limited, at least in rats, but
there are marked species differences in rodents
in metabolism and excretion of this and proba-
bly other PBDE congeners. 
Limited metabolism and excretion of
another PBDE congener, BDE-99 (a
pentaBDE), was observed in rats (86). Small
amounts of mono-hydroxylated metabolites of
penta- and tetraBDE were detected in feces,
which indicates in vivo debromination. Mono-
and dihydroxy pentaBDEs as well as two thio-
substituted pentaBDEs were detected in bile. 
Methoxylated PBDE congeners have been
identified in Swedish fish and seal samples
(13). These compounds may have been
formed by in vivo methylation of hydroxy-
lated PBDE metabolites. On the other hand,
microbial formation or other biogenic sources
are also possible. 
In a toxicokinetic study (53), rainbow
trout were administered technical decaBDE
(containing small amounts of nona- and
octaBDE) in the diet. PBDEs levels in muscle
were monitored during a depuration period
in clean water. The analysis revealed decreas-
ing levels of decaBDE, whereas levels of
BDE-153 increased continuously during the
depuration period. The results indicate meta-
bolic debromination of decaBDE to BDE-
153 in ﬁsh. 
Microsomal enzyme induction. PBDEs
are able to induce both phase I and phase II
xenobiotic metabolizing enzymes. Regarding
the cytochrome P450 (CYP)-mediated phase
I metabolism, CYP1A1 and CYP1A2 were
induced, as indicated by the increased activity
of liver microsomal 7-ethoxyresorufin O-
deethylase (EROD) activity after Bromkal 70
exposure in Wistar rats (84) and in H-4-II
cells (87). The other enzymes used as indica-
tors of microsomal phase I activity,
benzphetamine N-demethylase, p-nitroanisole
demethylase, arylhydrocarbon hydroxylase
(AHH), and benzo[a]pyrene hydroxylase,
were also induced by PBDEs (technical
pentaBDE preparations in rats) (84,88,89).
Some of the enzymes were induced in a long-
term oral administration study at doses as low
as approximately 1 µmol/kg/day, and the
enzyme activities continued 30–60 days after
termination of the exposure (89). The full-
brominated decaBDE, however, appears to
have low enzyme-inducing potency. 
The effects of BDE-47 and Aroclor 1254
on microsomal enzyme induction was studied
in Sprague-Dawley rats (90). Induction of
EROD and 7-methoxyresoruﬁn-O-deethylase
activities by BDE-47 was limited, in contrast
to the marked induction (> 100-fold) in
Aroclor-exposed animals. The effect on the
pentoxyresorufin analog, known to describe
CYP2B activity, was, on the other hand,
almost the same after treatment with both
BDE-47 and Aroclor 1254. If induction
capacity is indicative of metabolic pathways of
these compounds, the CYP2B enzymes may
be important in the metabolism of PBDEs.
In a recent study using a recombinant rat
hepatoma cell line H4IIE with a luciferase
reporter gene, several PBDE congeners acted
as Ah-receptor agonists (91). In this model
potencies of the agonists were comparable to
those of some mono-ortho PCBs. Some
PBDE congeners also had antagonistic effects
on TCDD-induced luciferase production.
Halogenated dioxinlike compounds typi-
cally induce CYP1A1 and 1A2. Therefore,
enzyme induction may be due to impurities
with Ah-receptor binding affinity present in
technical PBDE mixtures. It was shown that
PCDF impurities at concentrations < 1%
could completely account for the observed
EROD activity of all except one of 29 tested
polychlorinated diphenyl ether (PCDE) con-
geners (92). This study demonstrated that in
studies with halogenated DEs, it is important
to control the presence of potent dibenzofuran
and dibenzodioxin impurities, which even at
low concentrations can account for consider-
able biologic activity attributed to the relatively
high dosages required for DEs. The outcome
of this study is in agreement with structural
considerations suggesting that the nonplanarity
of halogenated DEs results in a low binding
afﬁnity to the Ah receptor (93). Nevertheless,
some studies have shown that pure PCDEs
indeed are weak inducers of microsomal
EROD and AHH activities in a congener- and
conformation-speciﬁc manner (94–97).
In studies on phase II induction, three
different PBDE fractions were tested; i.e., low
(24% tetra, 50% penta) and high (45%
hepta, 30% octa) brominated mixtures, and
the decaBDE congener only. After daily oral
administrations (14 days, 0.1 mmol/kg bw),
both of the mixtures, but not the decaBDE,
resulted in long-lasting induction of uridine
diphosphate glucuronyltransferase (UDPGT)
activity in rats (88). 
Human Data
As mentioned previously, PBDEs are found in
human blood and tissues and in human breast
milk. Data show that PBDEs are also
absorbed and retained in man and that BDE-
47 is the most abundant congener in most
cases. Today, data are too limited to estimate
the degree of human bioavailability and bioac-
cumulation. However, Sjödin (98) estimated
the elimination half-lives of certain PBDE
congeners in humans. Calculations were based
on blood levels taken before and after vacation
of workers in an electronics dismantling plant
(72). By this method, the estimated half-lives
of BDE-183 and BDE-209 were set to 86
days and 6.8 days, respectively. The levels of
BDE-47 and BDE-153 were also determined
in the same manner, but because no clear
decrease during vacation could be observed,
the half-lives could not be estimated.
These results suggest that the elimination
half-lives of PBDEs increase with degree of
bromination. This suggestion contrasts with
results in rats, where the reverse seems to be
true, at least regarding tetra- to hexaBDEs
(84). Results on elimination of PBDEs
increase with degree of bromination in
humans are quite different than those found
for PBBs and PCBs, where increases in
halogenation generally extend elimination
half-lives.
Toxicokinetics: Summary and
Conclusions
DecaBDE is minimally absorbed from the
gastrointestinal tract of mammals because of
its relatively high-molecular mass, and there-
fore it is unlikely to bioaccumulate. In fish,
however, uptake of decaBDE and subsequent
debromination to lower-brominated PBDEs
has been demonstrated. There is no informa-
tion on uptake or elimination of octaBDEs in
mammals. OctaBDEs are found in human
adipose tissue and in aquatic sediments, but
bioaccumulation is not likely to be substantial
because of low absorption. PentaBDEs are
found in biota, sediment, and sewage sludge
samples. They are likely to be persistent and
to bioaccumulate, and a bioconcentration fac-
tor of > 10,000 has been determined for carp.
A commercial tetraBDE mixture accumulates
and is persistent in many organisms in the
environment. 
Penta- and tetraBDEs are quite persistent
in the environment. Some mammalian
uptake and elimination studies suggest effec-
tive absorption and only moderate retention.
Considerable species differences have been
reported in metabolism and excretion of the
tetraBDE congener BDE-47. The rat appears
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to have a much slower metabolism and (uri-
nary) excretion than the mouse. Formation of
hydroxylated, thiol-substituted as well as
debrominated metabolites of BDE-47 and
BDE-99 has been demonstrated in rats.
Methoxylated PBDE analogs have been
found in samples from ﬁsh and seal. Possibly
they are formed by in vivo methylation of
hydroxylated PBDE metabolites or by micro-
biologic transformation. 
Toxicology
No complete toxicologic evaluation is cur-
rently available on any of the commercially
available PBDE mixtures or on any individual
congener. Most studies have been performed
using commercial PBDEs that are more or
less unspecified mixtures of congeners and
isomers. Consequently, a limited amount of
data is available about congener-specific
effects. An important question concerning
PBDEs is whether because of their structural
similarity to the highly toxic polyhalogenated
aromatic hydrocarbons, such as polyhalo-
genated biphenyls, dibenzo-p-dioxins, and
dibenzofurans, PBDE effects could occur by
the same mechanism(s) of toxicity. It is also
important to determine if contaminants in
technical PBDE mixtures exert toxic effects,
and if so, through which mechanism(s).
In this section, we examine available toxi-
city data on PBDEs. On the basis of existing
data, a lowest-observed-adverse-effect level
(LOAEL) value for the whole PBDE group is
proposed. The collected data are used in the
next section, “Toxicological Evaluation.”
Experimental Studies in Animals
Toxicologic information on PBDEs is based
on both published studies and research reports
made available recently by the chemical indus-
try (2,7). A summary of the data from studies
on the acute toxicity, irritation, sensitization,
genotoxicity and other short-term effects of
PBDEs is presented in Table 4. Available
Table 4. Summary of the acute toxicity, irritation, sensitization, genotoxicity, and porphyrinogenic activity of PBDEs.
Study PBDE Test system Result Reference
DecaBDE
Acute toxicity DecaBDE (commercial)
Oral LD50 Rat, f (Sprague-Dawley) > 2 g/kg bw (2,54,79)
Rat, m (Spartan) > 5 g/kg bw (2)
Dermal LD50 Rabbit, m+f /New Zealand white) > 2 g/kg bw (exposure for 24 hr) (2)
Inhalation LC50 > 48,2 mg/l (exposure for 1 hr) (2)
Rat, m+f (Spartan)
Skin irritation DecaBDE (commercial) Rabbit, m+f (New Zealand white) No irritation - slight erythema and edema  (2,54,79)
(on abraded skin)
Chloracnegenic activity Saytex 102a Rabbit, m+f (New Zealand white) Negative (2)
DecaBDE (commercial) Negative (2)
Rabbit (not speciﬁed)
Eye irritation Saytex 102 Rabbit, m+f (New Zealand white) Transient redness and chemosis (2,54,79)
Skin sensitization DecaBDE (commercial) Human volunteers Negative (2,54,79)
Genotoxicity
Mutagenicity HFO 102b S. typhimurium Negative (2)
Not speciﬁed S. cerevisiae Negative (2)
DecaBDE (commercial)  Mouse lymphoma L5178Y cells Negative (2)
Chromosomal effects DecaBDE (commercial) Chinese hamster ovary cells Negative (2)
DecaBDE (commercial) Rat bone marrow in vivo Negative (2,54,79)
Porphyrinogenic activity DecaBDE (commercial) Chick embryo liver cells Negative (100)
OctaBDE
Acute toxicity
Oral LD50 Not speciﬁed Rat (not speciﬁed) > 28 g/kg bw (2)
OctaBDE (commercial) Rat, m (Charles River CD) > 5 g/kg bw (2)
Dermal LD50 OctaBDE (commercial) Rabbit, m+f (albino) > 2 g/kg bw (exposure for 24 hr) (2)
Inhalation LC50 OctaBDE (commercial) Rat, m+f (Charles River CD) > 60 mg/L (exposure for 1 hr) (2)
Saytex 111c > 50 mg/L (2)
Rat (not speciﬁed)
Skin irritation OctaBDE (commercial) Rabbit, m+f (albino) No irritation - slight erythema (2)
Eye irritation OctaBDE (commercial) Rabbit, m+f (New Zealand white) No irritation - slight redness (2)
Genotoxicity OctaBDE (commercial)
DNA damage WI-38 human ﬁbroblasts Negative (2)
Mutagenicity S. typhimurium Negative (2)
S. cerevisiae Negative (2)
Chromosomal effects CHO cells Negative (2)
Porphyrinogenic activity OctaBDE (commercial) Chick embryo liver cells Strong porphyrinogenic effect (100)
PentaBDE
Acute toxicity
Oral LD50 PentaBDE (commercial) Rat, m (Charles River CD) 0.5 – 5 g/kg bw (2)
Rat, m+f (Wistar) m: 7.4 g/kg bw (2)
Dermal LD50 Rabbit, m+f (New Zealand white) > 2 g/kg bw (exposure for 24 hr) (2)
Inhalation LC50 Rat, m+f (Charles River CD) > 200 mg/L (exposure for 1 hr) (2)
Genotoxicity
Mutagenicity PentaBDE (commercial) S. typhimurium Negative (2)
S. cerevisiae Negative (2)
Porphyrinogenic activity DE-71d Rat, m+f (Sprague-Dawley CD) Highly increased concentrations of porphyrins  (2)
in liver and urine after oral dosing at 100 mg/kg 
bw/day for 13 weeks.
Abbreviations: f, female; m, male.
aSaytex 102 is a technical decaBDE product. bHFO 102 is a technical decaBDE product. cSaytex 111 is a commercial mixture containing pentaBDE, 0.2%; hexaBDE, 8.6%; heptaBDE, 45%; octaBDE, 33.5%;
nonaBDE, 11.2%; and decaBDE, 1.4% (2). dDE-71 is primarily a mixture of tetra-, penta-, and hexaBDE containing low levels of tri- (> 1%) and heptaBDE (< 2%) (2).
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information on subchronic and chronic toxic-
ity, carcinogenicity, and teratogenicity is given
in Table 5. 
Acute toxicity and local irritation. In gen-
eral, the acute toxicity of PBDEs (adminis-
tered orally, dermally, or by inhalation) is low
(Table 4). The low toxic potency of fully
brominated BDE-209 is likely to be
explained by poor absorption after oral
administration (54,60,79,80). Available data
are not suitable for use in even limited struc-
ture–toxicity correlations. PentaBDEs
appeared to be more toxic after oral adminis-
tration than octa- and decaBDEs, as they
caused clear signs of toxicity and mortality
primarily at high doses (oral LD50 in rats
0.5–5 g/kg or 7.4 g/kg, depending on the
study; Table 4). The clinical signs were
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Table 5. Summary of the repeated dose toxicity, carcinogenicity and special toxicity studies on PBDEs.
Dosage 
Study Species (strain) PBDE (purity) (mg/kg bw/day) Effects (dose level for observed effect) Reference
DecaPDE
Subacute toxicity Mouse (B6C3F1) DecaBDE (99%) In diet: 0, 3,000, 7,500 No compound-related effects (80)
(14 days) or 15,000a
Rat (Fischer 344/N) DecaBDE (99%) In diet: 0, 500, 2,000 No compound-related effects (80)
5,000 or 10,000a
Subacute toxicity Rat (Charles River CD) DecaBDE (commercial) In diet: 0, 10, or 100a No compound-related effects (2)
(28 days)
(30 days) Rat (Sprague-Dawley) DecaBDE (77.4%), In diet 0, 8, 80, or 800 Thyroid - hyperplasia (≥ 80); liver - enlarged (≥ 80); (2,54,79)
NonaBDE (21.8%), kidney - hyaline degeneration (≥ 80); hematocrit 
OctaBDE (0.8%) and red cell count - decreased (800)
Subchronic toxicity Mouse (B6C3F1) DecaBDE (> 97%) In diet: 0, 465, 930, No compound-related effects (80)
(13 weeks) 1,875, 3,750, or 7,500a
Rat (Fischer 344/N) DecaBDE (> 97%) In diet: 0, 310, 620, No compound-related effects; liver weights not recorded,  (80)
1,250, 2,500, or 5,000a in subsequent studies; liver - enlarged (≥ 2,500) 
Chronic toxicity, Mouse (B6C3F1) DecaBDE (94–99%) In diet: 0, 3,200, or  Liver - hypertrophy, granulomas, adenomas,  (80)
carcinogenicity 6,650 (males), 0, 3,760,  carcinomas (in males ≥ 3,200); thyroid - follicular
(103 weeks) or 7,780 (females) cell hyperplasia, adenomas, carcinomas (≥ 3,200)
Rat (Fischer 344/N) DecaBDE (94–99%) In diet: 0, 1,120, or  Liver - adenomas (≥ 1,120), thrombosis, degeneration  (80)
2,240 (males), 0, 1,200,  (in males 2,240); pancreas - acinar cell adenomas (in 
or 2,550 (females) males 2,240); spleen - hyperplasia (in males 2,240; 
lymphoid tissue - hyperplasia (in males 2,240)
OctaBDE
Subacute toxicity Rat (Charles River CD) OctaBDE (commercial) In diet: 0, 10, or 100a Liver - enlarged, cytoplasmic eosinophilic round  (2)
(28 days) bodies (≥ 10); thyroid - hyperplasia? (100)
Rat (Charles River CD) OctaBDE (commerical) In diet: 0, 10, 100, or Liver - hepatocytes enlarged with cytoplasmic eosinophilic  (2)
1,000a round bodies (≥ 10), whole liver enlarged (≥ 100), 
hepatocytes vacuolized with focal necrosis (1,000)
Subchronic toxicity Rat (Charles River CD) OctaBDE (commercial) In diet: 0, 10, 100, or Liver - enlarged, cytoplasm granular (≥ 10), hepatocytes  (2)
(13 weeks) 1,000a vacuolized, hyaline intracytoplasmic inclusions, hyper-
plastic nodules (≥ 100), accentuated lobulation, 
yellowish mottling, brownish discoloration, focal 
necrosis, centrilobular ﬁbrosis, pigmented Kupfer cells 
(1,000); thyroid - enlarged (≥ 100), cellular changes
(1,000); kidney - enlarged, cortical regenerative tubules, 
a single case of tubular nephrosis (1,000); hemoglobin, 
hematocrit, erythrocyte count - decreased (1,000); blood 
glucose - decreased (1,000); urine - orange discoloration 
(1,000); bw gain - decreased (≥ 100)
PentaBDE
Subacute toxicity  Rat (Charles River CD) PentaBDE (commercial) In diet: 0, 10, or 100a Liver - enlarged, cytoplasmic eosinophilic round bodies  (2)
(28 days) (≥ 10); thyroid - follicular hyperplasia? (≥ 10)
Subchronic toxicity  Rat (Sprague-Dawley  DE-71b In diet: 0, 2, 10, or 100 Serum thyroxin -decreased (≥ 10); thyroid hyperplasia - (2)
(90 days) CD) (≥ 10); liver - enlarged, hepatocytomegaly (≥ 10); liver and
urine porphyrins - increased (100); serum cholesterol -
increased (100); food consumption - decreased 
(in females 100); bw - decreased (100)
Special single dose Mouse (C57BL/6) DE-71b By gavage: 0, 0.8, 4, Serum thyroxin - decreased (≥ 0.8?) (104)
toxicity 20, 100, or 500
Special repeated dose Mouse (C57BL/6) DE-71b By gavage: 0, 18, 36, Serum thyroxin - decreased (≥ 18) (104)
toxicity (14 days) or 72
Mouse (C57BL/6 Bromkal 70-5 DEc By gavage: 0, 18, or 36 Serum thyroxin - decreased (≥ 18) (130)
Liver somatic index - increased (36)
Rat (Sprague-Dawley) Bromkal 70-5 DEc By gavage: 0, 18, or 36 Serum thyroxin - decreased (≥ 18) (130)
Liver somatic index - increased (36)
TetraBDE
Special repeated dose Mouse (C57BL/6) 2,2’,4,4’-TetraBDE By gavage: 0 or 18 Serum thyroxin - decreased (18) (130)
toxicity (14 days) (> 98%) Liver somatic index - increased (18)
Rat (Sprague-Dawley) 2,2’,4,4’-TetraBDE By gavage: 0, 1, 6, or 18 Serum thyroxin - decreased (18) (90)
(> 98%)
?, it was not clear for the authors of the original report whether or not the compound was compound related. 
aThe daily dose (in mg/kg bw/day) is estimated based on dietary PBDE concentrations and the generally used average daily food consumption of 10 g/day in young rats, 20 g/day in older rats, and 3 g/day
in mice. bDE-71 is primarily a mixture of tetra-, penta-, and hexaBDE containing low levels of tri- (> 1%) and heptaBDE (< 2%) (2). cBromkal 70-5 DE is a commercial mixture containing about 60%
pentaBDE and 40% tetraBDE (2).
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reduced growth, diarrhea, piloerection,
reduced activity, clonic persistent tremors of
forelimbs, red staining around eyes and nose,
and continuous chewing. Acute toxicity of
diBDE (purity and isomer profile not speci-
fied) has only been studied in mice after
intraperitoneal (ip) administration (2,99).
The ip LD50 value of 125 mg/kg clearly was
lower than those reported for the higher-
brominated congeners in rats after oral
administration. This difference, however,
does not conclusively reﬂect a higher potency
of diBDE; it may have resulted from different
routes of administration and differences in
species sensitivity.
Skin and eye irritation studies with octa-
and decaBDEs revealed only slight or no local
irritation in rabbits (2,54,79). DecaBDE was
not chloracnegenic in rabbits (2). In human
volunteers decaBDE did not cause skin irrita-
tion or skin sensitization (2,54,79).
Subacute/subchronic toxicity. Subacute/
subchronic oral toxicity studies in rats have
been carried out with deca-, octa- and
pentaBDE preparations (Table 5). In general,
effects were less pronounced with decaBDE
than with the other two congener groups.
Target organs were liver, kidney, and thyroid
gland. These organs were generally enlarged
with or without some degenerative changes.
In addition, hepatocellular necrosis was
observed in both oral and inhalation toxicity
studies with octaBDEs. Toxic effects were
noted at daily dietary doses of 10 mg/kg bw
and above for penta- and octaBDE. DecaBDE
was effective at 80 mg/kg bw in one study,
whereas another study showed effects only at
much higher doses or no effects at all (54,79).
Porphyrinogenic activity. Chronic hepatic
porhyria is a condition characterized by a
liver disorder resulting in production and
excretion of excess porhyrins. A commercial
octaBDE preparation (10 µg/mL) was
strongly porphyrinogenic in cultured chick
embryo liver cells after incubation for 24 hr
(100). Exposure of rats to a commercial
pentaBDE in the diet (100 mg/kg bw/day)
for 13 weeks resulted in highly increased liver
and urine concentrations of porphyrins
[unpublished data, cited in IPCS (2)]. It is
interesting to note that octa- and pentaBDEs
share the porphyrinogenic activity of dioxins,
PCBs, and PBBs (101–103). 
Immunotoxicity. In a study by Fowles and
co-workers (104), immunologic (and other)
effects of the PBDE preparation DE-71 [a
mixture of tetra-, penta-, and hexaBDE with
low levels of tri- (< 1%) and heptaBDE
(< 2%)] were monitored using sheep erythro-
cyte (SRBC) plaque-forming cell response and
natural killer (NK) cell activity. C57BL/56
mice were orally exposed to single DE-71
doses of up to 500 mg/kg, or to subcronic
daily doses of 72 mg/kg bw over a 14-day
period, totaling 1,000 mg/kg bw. Suppression
of the anti-SRBC response was seen only in
the mice exposed subchronically; this exposure
also resulted in decreased thymus weight. NK
cell activity was not altered.
Immunotoxic potential of Bromkal 70-
5DE (a commercial mixture containing about
60% of pentaBDE and 40% of hexaBDE) was
compared with that of a commercial PCB
preparation—Aroclor 1254—in Sprague-
Dawley rats and C57BL mice (105). The ani-
mals were given the preparations at 10–36
mg/kg bw/day for 14 days by oral gavage.
Mice were also exposed to BDE-47 and PCB-
105. The study showed that the exposure to
PCBs induces certain immunologic alterations
in both species, but signs of immunotoxicity
after PBDE exposure were observed only in
mice. The reduction in splenocyte numbers in
mice was markedly decreased after BDE-47
exposure (18 mg/kg/day). Moreover, Bromkal
70 treatment at 36 mg/kg resulted in decreased
production of IgG antibodies from pokeweed-
stimulated splenocyte cultures ex vivo.
In an in vitro study on cultured human
lymphocytes, the effects of two pure PBDE
congeners [BDE-47 and BDE-85 (2,2´,3,4,4´-
pentaBDE)] and three PCBs [2,3,3´,4,4´-
pentaCB (PCB-105), 2,3´,4,4´,5-pentaCB
(PCB-118), and 2,2´,4,4´,5,5´-hexachloro-
biphenyl (PCB-153)] on cell proliferation were
studied (106). None of the chemicals signiﬁ-
cantly altered the proliferative response com-
pared with control cells. Not even the PCBs
affected the lymphocyte proliferative response,
although PCBs are commonly known to be
immunotoxic in vivo. The known discrepan-
cies between in vivo and in vitro effects of poly-
halogenated aromatic hydrocarbons on
immunologic parameters may be a result of
indirect effects of these compounds on
immune function in vivo, e.g., via possible Ah
receptor-mediated hormone interactions
(107). Consequently, if PBDEs and PCBs
affect the immune system via the same mecha-
nism(s), this method may have limited rele-
vance for predicting the immunologic effects
of PBDEs in vivo.
The immunosuppressive potencies of
eight isomers of tetra-, penta-, or hexachlori-
nated DEs were determined using the mouse
splenic plaque-forming cell (PFC) response to
sheep red blood cell antigens (95). The iso-
mers dose dependently decreased the number
of PFCs, with ED50 values between 0.19 and
> 151 mg/kg (given as a single ip dose). The
immunotoxic effect appears to be highly iso-
mer speciﬁc, as there were remarkable differ-
ences between different isomers of penta- and
hexachlorinated DEs. 
Reproductive and developmental toxicity.
Reproductive toxicity of PBDEs has been
studied using commercial deca-, octa-, and
pentaBDE preparations and Saytex 111, a
commercial mixture of PBDEs containing
several congeners from penta- to decaBDE, of
which the hepta- and octaBDEs are most
abundant (45 and 34% of all congeners,
respectively) (Table 6). One of the studies is a
rat reproductive performance study with
decaBDE. All other studies are teratogenicity
studies, and only Saytex 111 has been studied
in both rats and rabbits.
Effects of decaBDE on reproductive per-
formance were studied in male and female
Sprague-Dawley (Spartan) rats given com-
mercial decaBDE in the diet in doses of 0, 3,
30, or 100 mg/kg bw/day (2,54,79). Group
sizes were 20 males and 40 females (control
group), 10 males and 20 females (the low-
and mid-dose group) and 15 males and 30
females (the highest-dose group). Treatment
began 60 days before mating and continued
throughout gestation and lactation. No treat-
ment-related changes were reported in repro-
ductive performance or maturation of pups.
In a teratogenicity study with Sprague-
Dawley (Spartan) rats, commercial decaBDE
was given in doses of 0, 10, 100, or 1,000
mg/kg bw/day by oral gavage on gestational
days 6–15; fetuses were collected by cesarean
section on gestational day 21 (2,54,79). No
maternal toxic effects in terms of clinical signs,
body weight gain, food consumption, or liver
weights were observed. Similarly, the number
of corpora lutea, positions and numbers of
fetuses in utero, individual fetal weights,
crown–rump lengths, and sex ratios were not
affected by the treatment. However, signifi-
cantly increased incidences of resorption were
observed at the lower dose levels but not at the
1,000 mg/kg bw/day dose. In the absence of
numeric as well as historical control data, the
possibility of embryolethality cannot be ruled
out. No external abnormalities were observed
in fetuses, but soft tissue and skeletal examina-
tions revealed an increased number of litters
with pups with subcutaneous edema and
delayed ossification of normally developed
bones of the skull at the dose level of 1,000
mg/kg bw/day. Analysis of maternal and fetal
livers for bromine concentration (reflecting
liver concentration of decaBDE) showed sig-
nificantly increased concentrations only in
maternal livers at the 1,000 mg/kg bw/day
dose. Although this study is inadequately
reported, it suggests that decaBDE is not ter-
atogenic but clearly fetotoxic at dose levels not
maternally toxic.
Teratogenicity of a commercial octaBDE
preparation was studied in rats (strain and
number of animals not speciﬁed) receiving the
test compound by gavage at 0, 2.5, 10, 15, 25,
or 50 mg/kg bw/day on gestational days 6–15
(2). Reduced maternal body weight gain and
slightly increased cholesterol levels, but no
histopathologic changes in livers or kidneys
were observed at the 50 mg/kg bw/day. These
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maternal effects were associated with marked
fetal toxicity as indicated by increased num-
bers of late resorptions, signiﬁcantly reduced
mean fetal weights, severe generalized edema
(anasarca), reduced ossification of the skull,
and various unossified bones. In addition,
developmental variations such as bent limb
bones and bent ribs were reported at the 50
mg/kg bw/day dose. No treatment-related
effects were observed at 15 mg/kg bw/day or
lower, but the findings at 25 mg/kg bw/day
were not discussed. Therefore, the no-
observed-effect level (NOEL) for maternal
toxicity is 25 mg/kg bw/day and for fetal
effects 15 mg/kg bw/day (2).
Teratogenicity of the commercial Saytex
111 mixture was studied in four groups of 25
Charles River (Sprague-Dawley) rats (63).
They were administered corn oil suspensions
of the test substance by gavage at 0, 2.5, 10,
or 25 mg/kg bw/day on gestational days
6–15. Fetuses were examined on day 20 for
gross visceral and skeletal abnormalities. The
test substance was found to be more toxic to
the fetuses than to the dams. It resulted in a
dose-dependent reduction of fetal body
weight at the two highest dose levels. At 25
mg/kg/day it also increased the number of
early and late resorptions, delayed skeletal
ossiﬁcation, and induced fetal malformations
such as enlarged heart and rear limb malfor-
mations (type of malformation not speciﬁed).
Teratogenicity of Saytex 111 was also
studied in groups of 26 New Zealand white
rabbits by the Dow Chemical Company
(108). The rabbits were administered the test
substance by gavage at 0, 2, 5, or 15 mg/kg
bw/day on gestational days 7–19, and the
fetuses collected on gestational day 28.
Approximately half of the fetuses in each lit-
ter were randomly assigned for soft tissue
examination. In addition, all fetuses were
examined for skeletal alterations. Maternal
body weight showed a dose-dependent
decrease that was statistically signiﬁcant only
at 15 mg/kg bw/day (93% of control weight).
Also, the absolute and body weight-related
liver weights were increased at this dose level.
One rabbit at 5 mg/kg bw/day and two rab-
bits at 15 mg/kg bw/day delivered their litters
prior to gestational day 28. In addition, one
rabbit at 15 mg/kg bw/day was killed after
exhibiting signs of abortion. This animal had
multiple resorption sites in the uterus. Except
for these animals, the number of resorptions
was not affected by the treatment. Signs of
fetal toxicity were slight (nonsignificant)
decreases in fetal body weights at 5 and 15
mg/kg bw/day and increased incidences of
delayed ossification of the hyoid, dental
process (at 5 mg/kg/day only), and sternebrae
at 2, 5, and 15 mg/kg bw/day (statistically
significant only at 15 mg/kg bw/day).
Treatment-related fetal variants included
increased incidences of retrocaval ureter and
fused sternebrae at all dose levels of Saytex
111, with the maximum incidence at 5
mg/kg/day (statistically significant). These
variants were absent from the concurrent
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Table 6. Summary of the reproduction and developmental toxicity studies on PBDEs.
Dosage 
Study Species (strain) PBDE (purity) (mg/kg bw/day) Effect (dose level for observed effect) Reference
DecaBDE
Reproductive Rat (Sprague-Dawley) DecaBDE (77,4%), In diet: 0, 3, 30, or 100 No compound-related effects (2,54,79)
performance NonaBDE (21.8%),
OctaBDE (0.8%)
Teratogenicity Rat (Sprague-Dawley) DecaBDE (77.4%) By gavage: 0, 10,  Fetal toxicity - resorptions (100), subcutaneous (2,54,79)
NonaBDE (21.8%) 100, or 1000 edema, delayed ossiﬁcation (1,000)
OctaBDE (0.8%)
OctaBDE
Teratogenicity Rat (not speciﬁed) DE-79 By gavage: 0, 2.5, 10 Fetal toxicity - late resorptions, weight decreased, (2)
15, 25 ,or 50 anasarka, bent limp bones, reduced ossiﬁcation, 
bent ribs (50); maternal toxicity - bw
decreased, serum cholesterol increased (50)
Teratogenicity Rat (Charles River Crb:  Saytex 111a By gavage: 0, 2.5, 10, Fetal toxicity - weight decreased (≥ 10, resorptions (63)
COBS CD (SD) BR) or 25 delayed ossiﬁcation (25); fetal variations/
malformations - enlarged heart, rear limb 
malformation (25)
Rabbit (New Zealand Saytex 111a By gavage: 0, 2, 5, or 15 Fetal toxicity - delayed ossiﬁcation (≥ 2), weight (108)
white) decreased (≥ 5), resorptions? (15); fetal variations/
malformations - retrocaval ureter (≥ 5), fused
sternebrae (5); maternal toxicity - bw 
gain decreased, liver enlarged (15)
PentaBDE
Teratogenicity Rat (not speciﬁed) PentaBDE (commercial) By gavage: 0, 10, 100, Maternal toxicity - bw gain decreased (2)
or 200  (≥ 100); fetal toxicity - weight decreased (200)
Special Mouse (NMRI) 2,2’, 4,4’,5-PentaBDE By gavage: 0, 0.8, or 12 Developmental neurotoxicity - impaired  (111)
developmental on postnatal day 10 habituation (locomotion, rearing, total activity)
toxicity in adulthood; worsens with aging; impaired learning
and memory functions (12)
Special Mouse (not speciﬁed) 2,2’,4,4’,5-PentaBDE By gavage: 0 or 8 on Developmental neurotoxicity - impaired  (113)
developmental postnatal day 3, 10, spontaneous motor behavior in adulthood;
toxicity or 19 nicotine-induced hypoactivity (8)
Special Rat (not speciﬁed) DE-71b By gavage: 0, 1, 10, Offspring toxicity - serum thyroxin decreased (≥ 1) (132)
developmental or 30 to dams on Maternal toxicity - serum thyroxin decreased (30)
toxicity gestational day 6–
postnatal day 21
TetraBDE
Special Mouse (NMRI) 2,2’,4,4’-TetraBDE By gavage: 0, 0.7, or  Developmental neurotoxicity - impaired  (111)
developmental 10.5 on postnatal  habituation (locomotion, rearing, total 
toxicity day 10 activity) in adulthood; worsens with aging (10.5)
aSaytex 111 is a commercial mixture containing pentaBDE, 0.2%; hexaBDE, 8.6%; heptaBDE, 45%; octaBDE, 33.5%; nonaBDE, 11.2%; and decaBDE, 1.4% (2). bDE-71 is primarily a mixture of tetra-, penta,
and hexaBDE containing low levels of tri- (> 1%) and heptaBDE (> 2%) (2).
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controls, but they were reported to have
occurred at relatively high frequencies among
some historical controls. This fact and the
lower incidence at 15 mg/kg bw/day com-
pared to 5 mg/kg bw/day led the authors
(108) to consider these variants spontaneous.
Nevertheless, we consider that the results
indicate a PBDE-induced increase in the inci-
dence of fetal variations. Isolated incidences
of fetal malformations were observed in all
groups including controls, but they were not
considered to represent a teratogenic effect.
We concluded that Saytex 111 caused fetal
toxicity and variants at maternally nontoxic
dose levels.
A teratogenicity study with a commercial
pentaBDE preparation was carried out in rats
(strain and number of animals not speciﬁed)
(2). The test compound was suspended in
corn oil and given by gavage at 0, 10, 100, or
200 mg/kg/day on gestational days 6–15.
Maternal body weight gain was decreased at
100 and 200 mg/kg/day, and a slight (non-
significant) reduction of fetal body weight
was observed at 200 mg/kg/day.
Treatment of pregnant mice and rats with
certain pure PCDE congeners on gestational
days 6–15 resulted in embryolethality as indi-
cated by the decreased number of litters or
pups born to dams administered the 100
mg/kg/day dose (109). In mice, the most
potent congeners were 2,3´,4´,6-tetraCDE
and 2,2´,4,5,6´-pentaCDE, but also
2,2´,4,4´,5,6´-hexaCDE and 2,2´,4,4´,5,5´-
hexaCDE caused a slight but statistically sig-
nificant effect. The other five congeners
studied did not show any signs of embryo-
toxicity at dose levels up to 100 mg/kg/day. In
rats, 2,3´,4´,6-tetraCDE, 2,2´,4,5,6´-
pentaCDE and 2,2´,4,4´,5,6´-hexaCDE were
studied; all were embryotoxic in terms of
number of pups born or pup weight. No
structural hallmarks in the PCDE molecule
related to embryotoxicity could be established.
However, a common feature of the congeners
causing prenatal mortality was at least two
chlorine substituents at the ortho position
(although not all congeners with this property
caused prenatal mortality). Induction of CYP
enzymes did not correlate well with the ability
of the congeners to cause embryotoxicity.
Reproduction and developmental toxicity
studies showed that in general fetuses are more
sensitive to PBDEs than mothers, and that the
increased incidence of developmental variants
is a frequent fetal effect. Although it is known
that maternal toxicity can inﬂuence fetal ossi-
ﬁcation (110), the fetal effects seem to appear
at lower doses than those indicative of mater-
nal toxicity (manifested as decreased bw gain
and increased liver weight in some cases).
Neurotoxicity. The developing central ner-
vous system is a potential target for toxicity of
PBDEs. Neonatal mice given a single oral
dose of BDE-47 (10.5 mg/kg bw) or BDE-99
(12.0 mg/kg bw) on postnatal day 10 (coinci-
dent with the rapid brain growth period) had
permanent impairment of spontaneous motor
behavior in adulthood (111). The latter con-
gener also affected learning and memory func-
tions. Further studies with BDE-99 conﬁrmed
these permanent behavioral effects (112,113).
Furthermore, studies with 14C-BDE-99
revealed concentrations in the brains of 10-
day-old mice similar to those observed for
other substances (DDT and certain PCB
congeners) that induced the same type of
behavioral effects in earlier studies. The neu-
rodevelopmental toxicity of PBDEs appears to
involve changes in the cholinergic system and
may also be related to altered thyroid home-
ostasis. The latter hypothesis is based on the
fact that brain development is highly depen-
dent on thyroid hormones (114). PCBs and
PCDDs that, like PBDEs, alter the thyroid
hormone homeostasis have been suggested to
disrupt brain development, resulting in per-
manent neurologic damage (115,116). 
Genotoxicity. The genotoxic potential of
commercial grade deca-, octa-, and pentaBDEs
has been examined in several, mostly unpub-
lished, studies (2). Mutagenicity tests carried
out on four strains of Salmonella typhimurium
with a technical product of decaBDE (HFO-
102) and commercial decaBDE with and
without metabolic activation were negative.
Similarly, studies in eukaryotic cells utilizing
yeast (Saccharomyces cerevisiae) and the TK
locus of the mouse lymphoma cell line
L5178Y with and without metabolic activation
were negative. Commercial decaBDE did not
induce chromosomal aberrations or sister chro-
matide exchanges in Chinese hamster ovary
cells with or without metabolic activation.
Results were also negative in cytogenetic exam-
ination of bone marrow cells from parent rats
exposed to decaBDE (at dose levels up to 100
mg/kg/day in a reproduction study) and their
weanlings (54,79).
A commercial octaBDE preparation was
found to be negative in unscheduled DNA syn-
thesis assay in the human fibroblast cell line
WI-38 with and without metabolic activation.
It neither induced mutations in S. typhimurium
or S. cerevisiae nor caused sister chromatide
exchanges in Chinese hamster ovary cells with
or without metabolic activation. Mutagenicity
studies with a commercial pentaBDE prepara-
tion in four strains of S. typhimurium and in S.
cerevisiae with and without metabolic activation
were all negative (2).
In two assays for intragenic recombina-
tion at an endogenous mammalian cell locus,
lower-brominated DEs (2-monobromoDE
and 3,4-dibromoDE) as well as other bromi-
nated ﬂame retardants (TBBP-A and HBCD)
signiﬁcantly increased the recombination fre-
quency (117). The possible role of this type
of increased intragenic recombination in
human diseases remains to be clariﬁed.
In conclusion, these studies, although not
complete state-of-the-art genotoxicity test
batteries, suggest that none of the PBDEs
examined are genotoxic. However, the possi-
ble increase in intragenic recombination, as
observed for the low-brominated DEs, should
be noted. 
Carcinogenicity. Rodent carcinogenicity
bioassays have been carried out only for
decaBDE (2,118). A mouse study and a rat
study have been reported in the National
Toxicology Program (NTP) report (80)
(Table 4), and a rat study of limited value has
been conducted by the Dow Chemical
Company (83).
In the NTP mouse study (80), decaBDE
(purity 94–99%; no brominated dioxins or
furans found) mixed in the diet was given to
groups of 50 male and 50 female B6C3F1 mice
for 103 weeks; all survivors were killed at
112–113 weeks of age. The concentration of
decaBDE in the diet was 0, 25, and 50 g/kg.
The average daily exposure to decaBDE was
estimated to be 3,200 and 6,650 mg/kg bw/day
in low- and high-dose males, respectively, and
3,760 and 7,780 mg/kg bw/day in low- and
high-dose females. Body weight development
and survival of decaBDE-treated mice were
comparable to those in controls. Liver granulo-
mas were observed in low-dose males and liver
hypertrophy in low- and high-dose males.
Signiﬁcantly increased combined incidence of
hepatocellular adenomas and carcinomas was
observed in male mice (8/50 in controls, 22/50
in low-dose, and 18/50 in high-dose males;
trend not signiﬁcant), whereas the combined
incidences of thyroid follicular cell adenomas
and carcinomas in males (0/50 in controls,
4/50 in low-dose, and 3/50 in high-dose males)
and females (1/50 in controls, 3/50 in low-
dose, and 3/50 in high-dose females) were
increased only nonsigniﬁcantly. Furthermore,
follicular cell hyperplasia was increased at both
dose levels in males and females.
In a study by the Dow Chemical
Company (83), groups of 25 male and 25
female Sprague-Dawley rats were given
“decaBDE” (containing decaBDE 77.4%,
nonaBDE 21.8%, and octaBDE 0.8%) in the
diet for 100–105 weeks. The dose levels were
0, 0.01, 0.1, and 1 mg/kg/day. The treatment
did not have any inﬂuence on survival rates,
appearance, body weights, feed consumption,
hematology, urinalysis, or organ weights.
There were no other discernible toxic effects,
and no significant differences in number of
rats developing tumors between the groups.
The International Agency for Research on
Cancer (IARC) Working Group pointed out
that the dose levels were very low (2).
In the NTP rat study (80), groups of 50
male and 50 female Fischer 344/N rats
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received decaBDE (purity 94–99%; no
brominated dioxins or furans found) mixed
in the diet for 103 weeks, all survivors were
killed at 111–112 weeks of age. The concen-
tration of decaBDE in the diet was 0, 25, and
50 g/kg diet, and the estimates for average
daily doses of decaBDE were 1,120 and
2,240 mg/kg bw/day in low- and high-dose
males, respectively, and 1,200 and 2,550
mg/kg bw/day in low- and high-dose females,
respectively. Body weights of the decaBDE-
treated rats were not significantly different
from those of controls. After week 75 survival
rates of the treated groups were lower than
those of controls. In high-dose males, throm-
bosis and degeneration of the liver, ﬁbrosis of
the spleen, and lymphoid hyperplasia were
observed. The incidences of neoplastic nod-
ules of the liver (adenomas) were signiﬁcantly
increased in both males (1/50 in controls,
7/50 in low-dose, and 15/49 in high-dose
males; p < 0.001, incidental tumor test for
trend) and females (1/50 in controls, 3/49 in
low-dose, and 9/50 in high-dose females;
p = 0.002, incidental tumor test for trend).
However, no differences in incidences of
hepatocellular carcinomas were detected
among the groups. Significantly increased
incidences of acinar cell adenomas of the pan-
creas was observed in males (0/49 in controls,
0/50 in low-dose, and 4/49 in high-dose rats;
p = 0.017, incidental tumor test for trend).
Additionally, high incidences of mononuclear
cell leukemia were observed in treated and
control rats of both sexes.
These studies have led to a conclusion
that there is limited evidence for carcino-
genicity of decaBDE in experimental animals,
and that decaBDE is not classiﬁable as to its
carcinogenicity to humans (Group 3) (118).
The lack of genotoxicity suggests that the
mechanism of the possible carcinogenicity of
decaBDE would be epigenetic.
Ah receptor-mediated effects. Polyhalo-
genated aromatic hydrocarbons exert many
different mechanisms of toxicity. One they
share in common, however, may be the Ah
receptor (AhR) binding effects (96). The best
characterized and one of the most sensitive of
the AhR-mediated phenomena is the induc-
tion of isoenzymes CYP1A1 and CYP1A2,
but the role of AhR in mediating toxic effects
is less understood. Recent studies in AhR-
deﬁcient mice, however, strongly suggest that
at least TCDD-induced thymic atrophy and
the most characteristic liver lesions would be
mediated by the AhR (119). 
Several studies have shown that PBDEs
may induce several microsomal enzyme activ-
ities. One of these, EROD, is a marker of
AhR binding. In a study by von Meyerinck
and co-workers (84) the same levels of
EROD induction were observed after expo-
sure of rats to pentaBDE as after Aroclor
1254 treament (both given as a single dose of
300 mg/kg bw). However, Hallgren and
Darnerud (90) observed a much weaker
induction by BDE-47 than Aroclor 1254
when given orally to rats in isomolar doses. 
The AhR agonist and antagonist activities
of a series of 17 PBDE isomers were recently
studied using a recombinant H4IIE rat
hepatoma cell line with a luciferase reporter
gene, the CALUX-assay (91). Seven of the
congeners induced luciferase expression,
whereas nine congeners decreased TCDD-
induced luciferase expression. Thus, some
pure PBDE congeners acted via the AhR sig-
nal transduction pathway as antagonists, ago-
nists, or both. Their potencies, however, were
approximately six orders of magnitude lower
than that of TCDD but comparable to those
of some mono-ortho PCBs such as PCB-105
and PCB-118 (120). The above studies sug-
gest that PBDEs may have certain AhR bind-
ing activities, although results deviate.
However, it seems less likely that the AhR
would have any major role in mediating toxic
effects of pure PBDEs.
Effects on thyroid hormones. Several
studies have demonstrated that exposure to
dioxins and related compounds are associated
with complex alterations in thyroid function
(121–123). These alterations include two dif-
ferent basic mechanisms. First, there is
increased elimination of thyroid hormones,
especially thyroxin (T4), primarily because of
induced activity of UDPGT in liver, which
leads to accelerated hepatic clearance of T4.
This has been reflected consistently in
decreased serum levels of total and free T4.
Alterations of 5´-deiodinase activities may
also change serum and tissue levels of thyroid
hormones (124). Second, many organohalo-
gen compounds structurally resemble thyroid
hormones and therefore compete for binding
to thyroid hormone receptors and transporter
proteins (121,125,126). In fact, halogenated
DEs appear to bind to the thyroid hormone
receptor with higher afﬁnity than planar lig-
ands do (93), and therefore PBDEs are likely
to be more potent thyroid agonists (or antag-
onists) compared with many other classes of
organohalogen compounds. Hydroxylated
PBDE metabolites are of particular interest
because thyroid hormones are also hydroxy-
halogenated DEs. Hydroxylated PBDE con-
geners 4´-OH-1,3,3´,5-tetraBDE and
4´-OH-1,3,3´,5,5´-pentaBDE that theoreti-
cally show the highest structural similarity
with triiodothyronin (T3) and T4, respec-
tively, have the highest binding affinities to
the thyroid hormone receptors (127). The
binding afﬁnities, however, were about two to
three orders of magnitude lower than those of
the endogenous ligands T3 and T4. Another
potentially significant property of hydroxy-
lated PBDE metabolites is their ability to
disrupt the transportation of thyroid hor-
mones by displacing them from the thyroxin
plasma transporter, transthyretin (TTR). A
preliminary study revealed that several micro-
somal PBDE metabolites (not identiﬁed) are
potent competitors of T4 binding to human
TTR (128). Interestingly, metabolism of
BDE-47 by phenobarbital-induced micro-
somes (mainly CYP2B) resulted in a strong
increase in TTR binding, whereas β-naph-
thoflavone-induced microsomes (mainly
CYP1A1) did not. Binding to TTR has been
shown to be a general property for hydroxy-
lated metabolites of PCBs and of other
organohalogen compounds (123,129).
Recent studies have shown that PBDEs
share the general property of several
organohalogen compounds in lowering the
serum total and free T4 in mice and rats
(90,104,130). Significantly decreased serum
T4 concentrations were found in C57BL/6
mice treated orally with a commercial
pentaBDE mixture (DE-71), both after expo-
sure to a single dose of 0.8–500 mg/kg bw
and after daily exposure for 14 days to total
doses of 250–1,000 mg/kg bw, i.e., 18–71
mg/kg bw/day (104). Similarly, Sprague-
Dawley rats and C57BL/6 mice given daily
oral doses of Bromkal 70 for 14 days at total
dose levels of 0, 250, or 500 mg/kg bw (0,
18, or 36 mg/kg bw/day) showed signiﬁcant
dose-dependent decreased levels of plasma
total T4 (130). Rats proved to be more sensi-
tive than mice. The plasma thyroid-
stimulating hormone concentrations were
largely unaffected. The pure congener BDE-
47 was equally or more potent in decreasing
serum total T4 than the commercial
pentaBDE in mice suggesting that this effect
is not caused by impurities of the technical
grade PBDE mixture. In addition, the techni-
cal grade PCB mixture Aroclor 1254 (con-
taining about 5% pentaCB) and the pure
congener PCB 105 (a mono-ortho PCB with
some AhR binding affinity) were slightly
more potent than the PBDEs in causing these
effects in mice. In continued studies on
Sprague-Dawley rats, daily oral doses of
BDE-47 for 14 days resulted in signiﬁcantly
decreased serum levels of free T4 levels at 18
mg/kg bw/day and gave a NOEL for this
effect of 6 mg/kg bw/day (90). Moreover,
BDE-47 induced a synergistic effect with
technical preparations of PCBs or chlorinated
parafﬁns in decreasing T4 levels.
In addition to the decreased T4 observed
after treatment with lower brominated DEs,
indirect evidence suggests that decaBDE may
also affect thyroid function. Increased inci-
dences of thyroid follicular cell hyperplasia as
well as slightly increased incidences of follicular
cell adenomas and carcinomas were observed
in decaBDE-treated mice in the NTP carcino-
genicity bioassay (80). Furthermore, workers
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exposed to decaBDE, other PBDEs, and PBBs
had increased prevalence of primary hypothy-
roidism, although serum analysis did not con-
ﬁrm the exposure to decaBDE (131).
In a recent preliminary report, exposure
of pregnant rats to DE-71 from gestational
day 6 to postnatal day 21 at 0, 1, 10, or 30
mg/kg bw/day was shown to decrease serum
T4 dose dependently in dams, fetuses, and
offspring (132). In the offspring the decreases
were 25, 50, and 70% at 1, 10, and 30 mg/kg
bw/day, respectively, on postnatal days 4 and
14, but levels recovered to the control levels
by postnatal day 36. Thyroid toxicity was also
observed in rat pups prenatally exposed to
polychlorinated DEs (133). Significantly
decreased serum T4 levels were observed in
16-day old pups given three PCDE congeners
(2´,3,4,6´-tetraCDE, 2,2´,4,5,6´-pentaCDE,
or 2,2´,4,4´,5,5´-hexaCDE) at maternal dose
levels of 25–100 mg/kg/day on gestational
days 6–15. The maximum decrease generally
had been observed at the lowest dose level,
and therefore the NOEL could not be deter-
mined. At lower doses the T4 decrease was
shown in absence of any other toxic effect,
but the highest dose level (100 mg/kg
bw/day) caused embryolethality as the num-
ber of litters and the number of pups were
highly reduced. Decreased maternal T4 was
observed only after treatment with the tetra
and penta congeners at 100 mg/kg/day.
Serum T3 levels were unaffected in both pups
and dams. The decrease in T4 levels did not
correlate with the ability of the congener to
induce CYP enzymes.
Collectively, these studies demonstrate that
thyroid homeostasis is a sensitive target of
PBDEs. Because the development of the cen-
tral nervous system is highly dependent on
thyroid hormones, alterations in thyroid
homeostasis may result in permanent neurobe-
havioral defects (114,115). It may also be the
primary cause of neurodevelopmental toxicity
of PBDEs. Therefore, altered thyroid function,
especially during development, is likely to be
among the most important end points of toxi-
city in the risk assessment of PBDE.
NOELs and LOAELs. Data from effects
observed in experimental animals adminis-
tered PBDEs orally have been compiled in
Table 7. In this table, the NOELs and the
LOAELs of the various studies are given. In
general, the NOEL values are considerably
higher for the decaBDE group than for the
lower-brominated technical PBDE prepara-
tions and pure BDE-47. The most sensitive
end point of toxicity, as indicated by the
LOAEL values, was the decrease in serum T4
concentration. A LOAEL value of 0.8 mg/kg
bw after a single dose of Bromkal DE-71 was
observed in adult mice (104). In this study,
however, a dose–response relationship was
absent. In a recent preliminary report (132), a
LOAEL value of 1 mg/kg bw/day was
reported in rat offspring exposed to DE-71 in
utero and lactationally. A LOAEL of 2 mg/kg
bw/day for fetal toxicity was found after
exposure to the Saytex 111 mixture in rabbits
(108). In adult rats exposed to DE-71 for 90
days, a NOEL value of 2 mg/kg bw/day was
determined for decreased serum T4, thyroid
hyperplasia, and hepatocytomegaly (2).
Moreover, a NOEL of 1 mg/kg bw/day for
decaBDE (containing 77.4% decaBDE,
21.8% nonaBDE, and 0.8% octaBDE) was
derived from the Dow Chemical Company
carcinogenicity study on rats (83). This dose
level was the highest dose and it did not cause
any toxicity. A general limitation of the studies
on the technical PBDEs is that the purity was
not always determined and the contaminants
present were not evaluated for their possible
modulation of the observed effect. Considering
this, the studies on the pure BDE-47 congener
(> 98% pure) are of value, as they exclude the
contribution of possible contaminants to the
observed thyroxin-lowering effect, shown at
the dose of 18 mg/kg bw (90,130). Also, in a
preliminary report, extended studies by
Eriksson and co-workers on neurobehavior
showed effects of the single congener BDE-99
at 8 mg/kg bw (113).
Toxicity in Humans
DecaBDE is the only PBDE for which lim-
ited human data are available. Skin sensitiza-
tion potential of decaBDE (Dow Chemical
Company, Midland, Michigan USA); con-
taining 77.4% decaBDE, 21.8% nonaBDE,
and 0.8% octaBDE) was studied in 50 volun-
teers (54,79). A 5% suspension of decaBDE
in petrolatum was applied to the skin 3 times
per week for 3 weeks, followed by a challenge
treatment 2 weeks after the last application.
No skin sensitization responses were observed
during the study. Another skin sensitization
study was performed on 80 male and 120
female volunteers exposed to two batches of
decaBDE (purity not stated) (2). The volun-
teers were treated with nine induction patches
at 2-day intervals and the test substance was
kept in contact with skin for 24 hr. The
induction regimen was followed by a period
of 12 days without treatment, after which a
new skin site was used for a 24-hr challenge
patch. Skin reactions were observed at 24 and
48 hr after removal of the challenge patch.
The study revealed no evidence of skin sensi-
tization with either batch of decaBDE.
Workers exposed during manufacture to
PBBs and PBDEs, including decaBDE, were
reported to have higher-than-normal preva-
lencies of primary hypothyroidism and signif-
icant reductions in conducting velocities in
sensory and motor neurons but no other neu-
rologic or dermatologic changes (131). It was
not possible to conclude whether these
changes could be attributed to PBB or PBDE
exposure, but no decaBDE could be detected
in serum of the exposed workers.
Four epidemiologic studies have been
conducted on workers at facilities where
flame-retardant polymers were extruded (2).
The workers were potentially exposed to
brominated flame retardants, including
PBDEs and in some cases also to polybromi-
nated PBDDs and PBDFs. These studies
found no adverse effects attributable to expo-
sure to these chemicals.
Toxicology: Summary and Conclusions
Limited amounts of data are available about
the toxicity of PBDEs. Most of the studies
have been carried out using technical- or
commercial-grade PBDEs, the purity of
which has been known in several cases, but
the isomer composition unknown. Moreover,
often no data are available about possible
halogenated dioxinlike impurities. A general
concern about toxicity data is that many
studies are documents that are difficult to
obtain and may not have been subjected to
examination by independent referees.
Therefore, because the quality of these studies
cannot be verified, their relevance in some
cases may be questionable.
Available data suggest that the acute toxic-
ity of PBDEs is low, they have at most only
slightly irritating properties, and they are not
skin sensitizers. No severe signs of toxicity
were observed in subacute and subchronic
toxicity studies. Target organs were the liver,
kidney, and thyroid gland, which were
enlarged and/or showed mainly minor
histopathologic changes. Different PBDEs
seemed to have similar toxicologic profiles,
but in most studies decaBDE was less potent
than the other congeners. PBDEs were not
genotoxic in short-term tests. In carcinogenic-
ity studies with decaBDE (at very high doses),
increased incidences of hepatocellular and thy-
roid adenomas and carcinomas were observed
in mice, and increased incidences of hepato-
cellular adenomas and acinar cell adenomas
of the pancreas were observed in rats.
Reproduction toxicity studies revealed
increased sensitivity of pregnant animals and
fetuses to PBDEs. Except for pentaBDE, toxic
effects on fetuses were observed already at
dose levels not toxic to mothers. Fetal toxicity
was sometimes associated with low incidences
of developmental variants. Neurobehavioral
effects were seen in adult mice after single rel-
atively low oral doses of tetra- and pentaBDEs
were given neonatally during the sensitive
brain growth period. Humans occupationally
exposed to PBBs and PBDEs were found to
have hypothyroidism and decreased conduc-
tion velocity of sensory and motor neurons,
but the association of these effects with expo-
sure to PBDEs was equivocal.
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Available evidence suggests that in spite of
certain structural similarity to dioxins,
PBDEs are weak agonists of the AhR. In fact,
observed AhR effects (e.g., CYP1A1 induc-
tion) may be at least partly attributed to their
highly potent polyhalogenated dioxin or
furan impurities. This coupled with the lack
of obvious dioxinlike toxic effects suggests
that the primary mechanisms of toxicity of
PBDEs are different from those of dioxins.
However, it appears likely that halogenated
DEs and their hydroxylated metabolites bind
effectively to transport proteins for thyroid
hormones, and that alteration of thyroid
homeostasis by this and perhaps also other
mechanisms may represent an important and
characteristic mechanism of toxicity of
PBDEs. 
The most sensitive end points of toxicity
determining LOAEL and NOEL values were
the hepatomegaly with cytoplasmic eosino-
philic “round bodies,” fetal and maternal
toxicity, and disturbances of thyroid home-
ostasis. Also, the recently discovered neuro-
toxic effect of several PBDE congeners at
relatively low levels should be noted. These
effects and their signiﬁcance therefore should
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Table 7. NOEL and LOAEL values of orally administered PBDEs in different toxicity studies.
NOEL (mg/kg  LOAEL (mg/kg 
Study Species PBDE (purity) bw/day) bw/day) Effect Reference
DecaBDE
Subacute toxicity Mouse DecaBDE (99%) 15,000 — — (80)
(14 days) Rat DecaBDE (99%) 10,000 — — (80)
Subacute toxicity
(28 days) Rat DecaBDE (commercial) 100 — — (2)
(30 days) Rat DecaBDE (77.4%), nonaBDE 8 80 Thyroid - hyperplasia (54,79)
(21.8%), octaBDE (0.8%) Liver - enlarged
Subchronic toxicity Mouse DecaBDE (> 97%) 7,500 — (80)
(13 weeks) Rat DecaBDE (> 97%) 5,000 — (80)
Chronic toxicity, Mouse DecaBDE (94–99%) — 3 200 Liver - hypertrophy , granulomas adenomas,  (80)
carcinogenicity carcinomas; thyroid - follicular cell hyperplasia, 
adenomas, carcinomas
Rat DecaBDE (94–99%) — 1 120 Liver - adenomas (80)
Reproductive Rat DecaBDE (77.4%), nonaBDE 100 — (54,79)
performance (21.8%), octaBDE (0.8%)
Teratogenicity Rat DecaBDE (77.4%), nonaBDE — 10 Fetal toxicity (54,79)
(21.8%), octaBDE (0.8%) 1,000 — Maternal toxicity
OctaBDE
Subacute toxicity Rat OctaBDE (commercial) — 10 Liver - hepatocytes enlarged, cytoplasmic  (2)
(28 days) eosinophilic round bodies
Subchronic toxicity Rat OctaBDE (commercial) — 10 Liver - enlarged (2)
(13 weeks)
Teratogenicity Rat DE-79 15 50 Fetal toxicity (2)
25 50 Maternal toxicity
Teratogenicity Rat Saytex 111a 2.5 10 Fetal Toxicity (63)
25 — Maternal toxicity
Rabbit Saytex 111a — 2 Fetal toxicity (108)
5 15 Maternal toxicity
PentaBDE
Subacute toxicity Rat PentaBDE (commercial) — 10 Liver - enlarged, cytoplasmic eusinophilic  (2)
(28 days) round bodies; thyroid - follicular hyperplasia?
Subchronic toxicity Rat DE-71b 2 10 Serum thyroxin - decreased, thyroid hyperplasia;  (2)
(90 days) liver - enlarged, hepacytomegaly
Teratogenicity Rat PentaBDE (commercial) 100 200 Fetal toxicity (2)
10 100 Maternal toxicity
Special development Rat DE-71b — 1 Offspring toxicity: serum thyroxin decreased (132)
toxicity (maternal)
exposure on GD 6- 10 30 Maternal toxicity: serum thyroxin
PND 21) decreased
Special single dose Mouse DE-71b — 0.8 Serum thyroxin - decreased (104)
toxicity
Special repeated Mouse Bromkal 70-5DEc — 18 Serum thyroxin - decreased (130)
dose toxicity (14 days) Rat Bromkal 70-5DEc — 18 Serum thyroxin - decreased (130)
Special developmental Mouse 2,2’,4,4’,5-PentaBDE 0.8 12 Developmental neurotoxicity (111)
toxicity, single dose 
on PND 10
Special developmental Mouse 2,2’,4,4’5-PentaBDE — 8 Developmental neurotoxicity (113)
toxicity, single dose 
on PND 3, 10, or 19
TetraBDE
Special repeated dose  Mouse 2,2’,4,4’-TetraBDE — 18 Serum thyroxin - decreased (130)
toxicity (14 days) Rat 2,2’,4,4’-TetraBDE 6 18 Serum thyroxin - decreased (90)
Special developmental Mouse 2,2’,4,4’-TetraBDE 0.7 10.5 Developmental neurotoxicity (111)
toxicity, single dose 
on PND 10
Abbreviations: GD, gestational day; PND, postnatal day.
aSaytex 111 is a commercial mixture containing pentaBDE, 0.2%; hexaBDE, 8.6%; heptaBDE, 45%; octaBDE, 33.5%; nonaBDE, 11.2%; and decaBDE, 1.4% (2). bDE 71 is primarily a mixture of tetra-, penta,
and hexaBDE containing low levels of tri- (> 1%) and heptaBDE (< 2%) (2). cBromkal 70-5DE is a commercial mixture containing about 60% of pentaBDE and 40% of tetraBDE (2).
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be addressed in further toxicologic studies
with PBDEs.
Toxicologic Evaluation
PBDEs are accumulating in sediment and
biota and appear to bioconcentrate at least in
aquatic ecosystems. Relatively high levels
could be found in fatty fish, Baltic herring,
for example. However, analyses of terrestrial
mammals reveal low PBDE levels. This may
imply that for humans exposure to PBDEs
directly from the environment is low (except
for occupational exposure), but exposure my
occur indirectly through the intake of food
from aquatic ecosystems. An area of concern
is the increasing exposure of infants to
PBDEs during lactation because of increasing
PBDE levels in mothers’ milk. Also, the pos-
sibility of long-term exposure from electronic
equipment such as computers should how-
ever not be ignored. Data on PBDE levels in
human tissues and fluids suggest an increas-
ing time trend, although levels are still con-
siderably lower than those of PCBs.
Data on rodents suggest that elimination
of PBDEs from the body is species dependent
(urinary excretion of BDE-47 is much higher
in mice than in rats). No clear differences in
body distribution between different con-
geners is seen in mice. Hydroxylated PBDE
metabolites were detected in the mouse and
the rat. The toxic potency of these metabo-
lites is unknown, but it is suggested that
hydroxylated PCB metabolites mimic both
thyroid hormones and estrogens. There is evi-
dence that debromination of PBDEs to lower
brominated DEs occurs in rodents and ﬁsh.
As nonplanar compounds, PBDEs do not
bind to the AhR with high affinity or exert
dioxinike toxicity. Part of the observed lim-
ited CYP1A1 induction may be explained by
potent halogenated dioxin and furan impuri-
ties which, even if present only at low con-
centrations, may become significant in
exerting these effects.
Effects on thyroid function, experimentally
observed primarily as T4 hypothyroidism,
appear to be sensitive end points of PBDE tox-
icity. Interestingly, primary hypothyroidism
has also been reported in humans after possible
occupational exposure. Other effects include
hepatotoxicity, developmental neurotoxicity,
and embryotoxicity as well as maternal toxicity
during gestation. Fetal effects observed in sev-
eral studies were delayed ossiﬁcation of bones,
bent ribs and bones, and decreased fetal
weight. Although not severe, such effects if
found at relatively low exposure levels are cause
for concern. Currently there are no reports
about effects of PBDE exposure on the human
fetus/offspring. However, the possibility of
these effects on humans should be considered. 
The NOEL values for fetal effects were
found at < 2 to 15 mg/kg bw/day (commercial
octa- and pentaBDEs). A LOAEL of 8 mg/kg
bw was seen in mice subjected to neurotoxic-
ity tests (BDE-99). Also, the effects on liver
and thyroid hormones occurred at relatively
low doses (NOEL 2–18 mg/kg bw/day).
Effects on thyroid hormones were observed at
an even lower dose, 0.8 mg/kg bw (but in the
absence of dose–response correlation), by
Fowles and co-workers (104). In a recent pre-
liminary study in rats, exposure to a com-
mericial PBDE mixture resulted in a LOAEL
of 1 mg/kg bw based on thyroid hormone
effects. Consequently, if the most sensitive
end points are chosen (although partly based
on a preliminary report on a technical
pentaBDE), a LOAEL value of 1 mg/kg/day
is reasonable for compounds or mixtures
belonging to the PBDE group. Using an
extrapolation factor of 10, a NOEL of 0.1
mg/kg/day could be suggested for the
PBDEs. More studies are needed, however, to
provide a better basis for risk assessment of
PBDEs and for producing a more solid
LOAEL and NOEL.
The preliminary estimated dietary PBDE
intake of 51 ng/day equals 0.7 ng/kg/day for a
person weighing 70 kg. Comparison of the
estimated dietary intake with the presented
LOAEL value of 1 mg/kg/day results in a
safety factor of > 106 with regard to the mean
PBDE exposure from food. However, special
dietary habits or other types of PBDE exposure
may decrease this safety factor considerably.
Data Gaps and Future
Research Needs
It is important to know the purity and impu-
rity profiles of PBDEs used for kinetic and
toxicity studies; these data should always be
available. To avoid impurity problems,
studies using isomer-specific pure congeners
should be encouraged.
Further studies on PBDE time trends are
needed to conﬁrm and extend earlier observa-
tions. Results from ongoing studies are impor-
tant in assessing resource needs for future
PBDE studies. It is currently known that cer-
tain PBDE congeners accumulate in the envi-
ronment, where others do not, but the reason
for this discrepancy is not understood.
Therefore, environmental transformation
studies are needed to examine, for example,
the degradation of decaBDE to penta- and
tetraBDEs. It is also important to collect more
data on human exposure, especially through
food, but also through other routes.
There still are large gaps in data concerning
PBDE toxicity. General toxicity studies should
be performed on speciﬁc congeners of impor-
tance in terms of environmental levels and
bioaccumulation, congeners such as BDE-47, -
99, -100 and -153. There are also large data
gaps in the field of toxicokinetics, i.e., the
metabolism of PBDEs, metabolites formed,
and enzymes involved. The following charac-
teristic and critical end points of PBDE toxic-
ity should be studied further: mechanisms of
thyroid toxicity, possible effects on other hor-
monal systems, and reproduction and develop-
mental toxicity. The latter should concentrate
especially on multigeneration studies and peri-
and postnatal toxicity and include neurotoxic-
ity models. It is also important to perform
cancer bioassays on the tetra- and pentaBDEs,
as these PBDE groups are bioavailable and are
often found in higher concentrations in the
environment than decaBDE. Finally, studies
on structure–activity relationships and interac-
tions (including synergism, antagonism, and
interactions with other halogenated aromatic
hydrocarbons) of PBDE are important for the
toxicologic evaluation of PBDEs.
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